


**CUMULATIVE
SUPPLEMENT 5
MAY 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 5

May 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement.....	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend.....	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List.....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution.....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists.....	A-1
B. Patent and Exclusivity Terms.....	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

**CUMULATIVE SUPPLEMENT 5
May 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> (FORMER ABBREVIATED NAME)	<u>NEW APPLICANT NAME</u> (NEW ABBREVIATED NAME)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352			
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)			
MULTISOURCE	13578 (84.1%)	13744 (84.1%)			
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)			
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)			
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	13	22			
NUMBER OF APPLICANTS	927	935			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL
FIORICET

@ ACTAVIS LABS UT INC 325MG; 50MG; 40MG A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG; 50MG; 40MG; 30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA SUN PHARM INDS LTD 300MG; 30MG A085868 001 Apr CAHN
AA 300MG; 60MG A087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG; 2.5MG A040846 001 Jun 09, 2010 Feb CTEC
@ SUN PHARM INDS LTD 325MG; 10MG A040826 001 Aug 16, 2007 Apr CAHN

NORCO
AA ACTAVIS LABS FL INC 325MG; 2.5MG A040148 004 Jul 07, 2014 Feb NEWA
AA 325MG; 5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA

ACITRETIN

CAPSULE; ORAL
ACITRETIN

>A> AB SIGMAPHARM LABS LLC 10MG A204633 001 May 22, 2015 May NEWA
>A> AB 17.5MG A204633 002 May 22, 2015 May NEWA
>A> AB 22.5MG A204633 003 May 22, 2015 May NEWA
>A> AB 25MG A204633 004 May 22, 2015 May NEWA

ACOLIDINIUM BROMIDE

POWDER, METERED; INHALATION
TUDORZA PRESSAIR

+ ASTRAZENECA PHARMS 0.375MG/INH N202450 001 Jul 23, 2012 Apr CAHN

ACYCLOVIR

TABLET; ORAL
ACYCLOVIR

AB SUN PHARM INDS LTD 400MG A074980 001 Sep 30, 1998 Apr CAHN
AB 800MG A074980 002 Sep 30, 1998 Apr CAHN

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

AP MYLAN PHARMS INC 3MG/ML A078686 001 May 13, 2009 Apr CAHN
>D> AP WOCKHARDT 3MG/ML A090220 001 Jul 20, 2009 May DISC
>A> @ 3MG/ML A090220 001 Jul 20, 2009 May DISC

ALBUTEROL SULFATE

POWDER, METERED; INHALATION
PROAIR RESPICLICK

+ TEVA BRANDED PHARM EQ 0.090MG BASE/INH N205636 001 Mar 31, 2015 Mar NEWA

SYRUP; ORAL

ALBUTEROL SULFATE

AA G AND W LABS INC EQ 2MG BASE/5ML A074454 001 Sep 25, 1995 Apr CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

>D> COMBIVENT

>D> + BOEHRINGER INGELHEIM EQ 0.09MG BASE/INH;0.018MG/INH N020291 001 Oct 24, 1996 May DISC

>A> @ EQ 0.09MG BASE/INH;0.018MG/INH N020291 001 Oct 24, 1996 May DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

@ WOCKHARDT LTD 10MG A090221 001 Aug 10, 2012 Feb DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

>D> TABLET; ORAL

>D> TEKAMLO

>D> NOVARTIS EQ 150MG BASE;EQ 5MG BASE N022545 001 Aug 26, 2010 May DISC

>A> @ EQ 150MG BASE;EQ 5MG BASE N022545 001 Aug 26, 2010 May DISC

>D> EQ 150MG BASE;EQ 10MG BASE N022545 002 Aug 26, 2010 May DISC

>A> @ EQ 150MG BASE;EQ 10MG BASE N022545 002 Aug 26, 2010 May DISC

>D> EQ 300MG BASE;EQ 5MG BASE N022545 003 Aug 26, 2010 May DISC

>A> @ EQ 300MG BASE;EQ 5MG BASE N022545 003 Aug 26, 2010 May DISC

>D> + EQ 300MG BASE;EQ 10MG BASE N022545 004 Aug 26, 2010 May DISC

>A> @ EQ 300MG BASE;EQ 10MG BASE N022545 004 Aug 26, 2010 May DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

>D> TABLET; ORAL

>D> AMTURNIDE

>D> NOVARTIS EQ 150MG BASE;EQ 5MG BASE;12.5MG N200045 001 Dec 21, 2010 May DISC

>A> @ EQ 150MG BASE;EQ 5MG BASE;12.5MG N200045 001 Dec 21, 2010 May DISC

>D> EQ 300MG BASE;EQ 5MG BASE;12.5MG N200045 002 Dec 21, 2010 May DISC

>A> @ EQ 300MG BASE;EQ 5MG BASE;12.5MG N200045 002 Dec 21, 2010 May DISC

>D> EQ 300MG BASE;EQ 5MG BASE;25MG N200045 003 Dec 21, 2010 May DISC

>A> @ EQ 300MG BASE;EQ 5MG BASE;25MG N200045 003 Dec 21, 2010 May DISC

>D> EQ 300MG BASE;EQ 10MG BASE;12.5MG N200045 004 Dec 21, 2010 May DISC

>A> @ EQ 300MG BASE;EQ 10MG BASE;12.5MG N200045 004 Dec 21, 2010 May DISC

>D> + EQ 300MG BASE;EQ 10MG BASE;25MG N200045 005 Dec 21, 2010 May DISC

>A> @ EQ 300MG BASE;EQ 10MG BASE;25MG N200045 005 Dec 21, 2010 May DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB ROXANE EQ 0.5MG BASE A200652 001 May 04, 2015 Apr NEWA

AB EQ 1MG BASE A200652 002 May 04, 2015 Apr NEWA

LOTRONEX

AB PROMETHEUS LABS EQ 0.5MG BASE N021107 002 Dec 23, 2003 Apr CFTG

AB + EQ 1MG BASE N021107 001 Feb 09, 2000 Apr CFTG

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB NATCO PHARMA LTD 0.25MG A200739 001 Apr 15, 2015 Mar NEWA

AB 0.5MG A200739 002 Apr 15, 2015 Mar NEWA

AB 1MG A200739 003 Apr 15, 2015 Mar NEWA

AB 2MG A200739 004 Apr 15, 2015 Mar NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB BANNER LIFE SCIENCES 100MG A078720 001 May 29, 2008 Jan CAHN

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

>D> @ ACTAVIS MID ATLANTIC 50MG/5ML A072655 001 Oct 30, 1990 May CAHN

>A> @ G AND W LABS INC 50MG/5ML A072655 001 Oct 30, 1990 May CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ IGI LABS INC EQ 50MG BASE/ML A063167 001 Dec 14, 1995 Mar CAHN

@ EQ 250MG BASE/ML A063169 001 Dec 14, 1995 Mar CAHN

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 4% (4GM/100ML) N018684 001 Sep 28, 1984 Feb DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML N020177 001 Oct 23, 1995 Feb DISC

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

>D> AA MIKART 1.25GM/5ML A074759 001 Sep 02, 1998 May CAHN
 >A> AA VERSAPHARM INC 1.25GM/5ML A074759 001 Sep 02, 1998 May CAHN

TABLET;ORAL

AMINOCAPROIC

>D> AB MIKART 500MG A075602 001 May 24, 2001 May CAHN
 >A> AB VERSAPHARM INC 500MG A075602 001 May 24, 2001 May CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB CHINA RESOURCES EQ 5MG BASE A090752 001 Apr 15, 2011 Mar CAHN
 AB EQ 10MG BASE A090752 002 Apr 15, 2011 Mar CAHN
 AB SUN PHARM INDS LTD EQ 2.5MG BASE A077974 001 Jul 09, 2007 Apr CAHN
 AB EQ 5MG BASE A077974 002 Jul 09, 2007 Apr CAHN
 AB EQ 10MG BASE A077974 003 Jul 09, 2007 Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>A> AB LUPIN LTD 5MG;12.5MG;160MG A200797 001 Jun 03, 2015 May NEWA
 >A> AB 5MG;25MG;160MG A200797 002 Jun 03, 2015 May NEWA
 >A> AB 10MG;12.5MG;160MG A200797 003 Jun 03, 2015 May NEWA
 >A> AB 10MG;25MG;160MG A200797 004 Jun 03, 2015 May NEWA
 >A> AB 10MG;25MG;320MG A200797 005 Jun 03, 2015 May NEWA
 >A> AB PAR PHARM 5MG;12.5MG;160MG A201087 001 Jun 01, 2015 May NEWA
 >A> AB 5MG;25MG;160MG A201087 002 Jun 01, 2015 May NEWA
 >A> AB 10MG;12.5MG;160MG A201087 003 Jun 01, 2015 May NEWA
 >A> AB 10MG;25MG;160MG A201087 004 Jun 01, 2015 May NEWA
 >A> AB 10MG;25MG;320MG A201087 005 Jun 01, 2015 May NEWA
 >A> AB TEVA PHARMS 5MG;12.5MG;160MG A200435 001 Sep 25, 2012 May CAIN
 >A> AB 5MG;25MG;160MG A200435 002 Sep 25, 2012 May CAIN
 >A> AB 10MG;12.5MG;160MG A200435 005 Sep 25, 2012 May CAIN
 >A> AB 10MG;25MG;160MG A200435 003 Sep 25, 2012 May CAIN
 >A> AB 10MG;25MG;320MG A200435 004 Sep 25, 2012 May CAIN
 >A> AB TORRENT PHARMS LTD 5MG;12.5MG;160MG A201593 001 Jun 04, 2015 May NEWA
 >A> AB 5MG;25MG;160MG A201593 002 Jun 04, 2015 May NEWA
 >A> AB 10MG;12.5MG;160MG A201593 003 Jun 04, 2015 May NEWA
 >A> AB 10MG;25MG;160MG A201593 004 Jun 04, 2015 May NEWA
 >A> AB 10MG;25MG;320MG A201593 005 Jun 04, 2015 May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

SYMPLMED PHARMS LLC EQ 2.5MG BASE;3.5MG N205003 001 Jan 21, 2015 Jan NEWA
 EQ 5MG BASE;7MG N205003 002 Jan 21, 2015 Jan NEWA
 + EQ 10MG BASE;14MG N205003 003 Jan 21, 2015 Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB ALEMBIC PHARMS LTD EQ 5MG BASE;160MG A202713 001 Apr 03, 2015 Mar NEWA
 AB EQ 5MG BASE;320MG A202713 003 Apr 03, 2015 Mar NEWA
 AB EQ 10MG BASE;160MG A202713 002 Apr 03, 2015 Mar NEWA
 AB EQ 10MG BASE;320MG A202713 004 Apr 03, 2015 Mar NEWA
 AB LUPIN EQ 5MG BASE;160MG A090245 001 Mar 30, 2015 Mar NEWA
 AB EQ 5MG BASE;320MG A090245 003 Mar 30, 2015 Mar NEWA
 AB EQ 10MG BASE;160MG A090245 002 Mar 30, 2015 Mar NEWA
 AB EQ 10MG BASE;320MG A090245 004 Mar 30, 2015 Mar NEWA

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A 090483	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A 090483	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A 090483	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A 090483	004	Mar 30, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A 090483	001	Mar 30, 2015	Apr	CAHN
AB		EQ 5MG BASE;320MG	A 090483	003	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;160MG	A 090483	002	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;320MG	A 090483	004	Mar 30, 2015	Apr	CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A 202829	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A 202829	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A 202829	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A 202829	004	Mar 30, 2015	Mar	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A 091235	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A 091235	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A 091235	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A 091235	004	Mar 30, 2015	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A 202377	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A 202377	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A 202377	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A 202377	004	Mar 30, 2015	Mar	NEWA

>D> AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

>D> TABLET;ORAL

>D> AMLODIPINE,VALSARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	TEVA PHARMS	5MG;12.5MG;160MG	A 200435	001	Sep 25, 2012	May	CAIN
>D>	AB		5MG;25MG;160MG	A 200435	002	Sep 25, 2012	May	CAIN
>D>	AB		10MG;12.5MG;160MG	A 200435	005	Sep 25, 2012	May	CAIN
>D>	AB		10MG;25MG;160MG	A 200435	003	Sep 25, 2012	May	CAIN
>D>	AB		10MG;25MG;320MG	A 200435	004	Sep 25, 2012	May	CAIN

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A 204352	001	May 01, 2015	Apr	NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A 204667	001	Apr 22, 2015	Apr	NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A 204515	001	Feb 04, 2015	Jan	NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A 204455	001	Apr 23, 2015	Apr	NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A 065016	001	Apr 08, 1999	Apr	CAHN
AB		500MG	A 065016	002	Apr 08, 1999	Apr	CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	200MG/5ML	A 065113	001	Nov 29, 2002	Apr	CAHN
@		400MG/5ML	A 065113	002	Nov 29, 2002	Apr	CAHN

TABLET;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A 065059	001	Nov 24, 2000	Apr	CAHN
AB		875MG	A 065059	002	Nov 24, 2000	Apr	CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A 065021	001	Dec 23, 1999	Apr	CAHN
@		200MG	A 065060	001	Nov 29, 2000	Apr	CAHN
AB		250MG	A 065021	002	Dec 23, 1999	Apr	CAHN
@		400MG	A 065060	002	Nov 29, 2000	Apr	CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A 065132	001	Mar 19, 2003	Apr	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A 065132	002	Mar 19, 2003	Apr	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A 065207	002	Jan 30, 2007	Apr	CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@	SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A 065109	001	Nov 04, 2002	Apr	CAHN
AB		875MG;EQ 125MG BASE	A 065102	001	Sep 17, 2002	Apr	CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A 065161	001	Dec 03, 2003	Apr	CAHN
AB		400MG;EQ 57MG BASE	A 065161	002	Dec 03, 2003	Apr	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A 040444	005	Nov 03, 2014	May	NEWA
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A 040444	006	Nov 03, 2014	May	NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A 040444	007	Nov 03, 2014	May	NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

		ARBOR PHARMS LLC	5MG	A 200166	001	Aug 09, 2012	Mar	CTNA
		+	10MG	A 200166	002	Aug 09, 2012	Mar	CTNA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

		@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A 061741	001		Apr	CAHN
--	--	--------------------	---------------------------	----------	-----	--	-----	------

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

		@ KREMERS URBAN PHARMS	1MG	A 091331	001	Jan 05, 2011	Mar	CAHN
--	--	------------------------	-----	----------	-----	--------------	-----	------

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP		FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N 201811	001	Mar 23, 2015	Apr	CDFR
----	--	--------------------	------------------------	----------	-----	--------------	-----	------

INJECTABLE;IV (INFUSION)

ARGATROBAN

AP		FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N 201811	001	Mar 23, 2015	Mar	NEWA
----	--	--------------------	------------------------	----------	-----	--------------	-----	------

ARIPIPIRAZOLE

SOLUTION;ORAL

ABILIFY

		@ OTSUKA	1MG/ML	N 021713	001	Dec 10, 2004	Apr	DISC
--	--	----------	--------	----------	-----	--------------	-----	------

TABLET;ORAL

ABILIFY

AB		OTSUKA	2MG	N 021436	006	Nov 15, 2002	Apr	CFTG
AB	+		5MG	N 021436	005	Nov 15, 2002	Apr	CFTG
AB	+		10MG	N 021436	001	Nov 15, 2002	Apr	CFTG
AB			15MG	N 021436	002	Nov 15, 2002	Apr	CFTG
AB			20MG	N 021436	003	Nov 15, 2002	Apr	CFTG
AB			30MG	N 021436	004	Nov 15, 2002	Apr	CFTG

ARIPIPIRAZOLE

AB		ALEMBIC PHARMS LTD	2MG	A 202101	001	Apr 28, 2015	Apr	NEWA
AB			5MG	A 202101	002	Apr 28, 2015	Apr	NEWA
AB			10MG	A 202101	003	Apr 28, 2015	Apr	NEWA
AB			15MG	A 202101	004	Apr 28, 2015	Apr	NEWA
AB			20MG	A 202101	005	Apr 28, 2015	Apr	NEWA
AB			30MG	A 202101	006	Apr 28, 2015	Apr	NEWA
AB		HETERO LABS LTD V	2MG	A 205064	001	Apr 28, 2015	Apr	NEWA
AB			5MG	A 205064	002	Apr 28, 2015	Apr	NEWA
AB			10MG	A 205064	003	Apr 28, 2015	Apr	NEWA
AB			15MG	A 205064	004	Apr 28, 2015	Apr	NEWA
AB			20MG	A 205064	005	Apr 28, 2015	Apr	NEWA
AB			30MG	A 205064	006	Apr 28, 2015	Apr	NEWA
AB		TEVA PHARMS USA	2MG	A 078607	001	Apr 28, 2015	Apr	NEWA
AB			5MG	A 078607	002	Apr 28, 2015	Apr	NEWA
AB			10MG	A 078608	001	Apr 28, 2015	Apr	NEWA
AB			15MG	A 078708	001	Apr 28, 2015	Apr	NEWA
AB			20MG	A 078708	002	Apr 28, 2015	Apr	NEWA
AB			30MG	A 078708	003	Apr 28, 2015	Apr	NEWA
AB		TORRENT PHARMS LTD	2MG	A 201519	001	Apr 28, 2015	Apr	NEWA
AB			10MG	A 201519	003	Apr 28, 2015	Apr	NEWA
AB			5MG	A 201519	002	Apr 28, 2015	Apr	NEWA
AB			15MG	A 201519	004	Apr 28, 2015	Apr	NEWA
AB			20MG	A 201519	005	Apr 28, 2015	Apr	NEWA

TABLET;ORAL							
ARIPIPIRAZOLE							
AB		30MG		A201519	006	Apr 28, 2015	Apr NEWA
TABLET, ORALLY DISINTEGRATING;ORAL							
ABILIFY							
AB	+	OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr CFTG
AB			15MG	N021729	003	Jun 07, 2006	Apr CFTG
ARIPIPIRAZOLE							
AB		ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr NEWA
AB			15MG	A202102	002	Apr 28, 2015	Apr NEWA
<u>ASPIRIN; BUTALBITAL; CAFFEINE</u>							
CAPSULE;ORAL							
FIORINAL							
AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan CAHN
TABLET;ORAL							
FIORINAL							
		@ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CAHN
<u>ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE</u>							
CAPSULE;ORAL							
FIORINAL W/CODEINE							
AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan CAHN
<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>							
TABLET;ORAL							
NORGESIC							
		@ MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar DISC
NORGESIC FORTE							
		@ MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar DISC
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE							
		SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar CTEC
	+		770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar CTEC
<u>ASPIRIN; OXYCODONE HYDROCHLORIDE</u>							
TABLET;ORAL							
OXYCODONE AND ASPIRIN							
AA		ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar CAHN
<u>ATAZANAVIR SULFATE; COBICISTAT</u>							
TABLET;ORAL							
EVOTAZ							
	+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan NEWA
<u>ATENOLOL</u>							
TABLET;ORAL							
TENORMIN							
AB		ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
AB			50MG	N018240	001		Feb CAHN
AB	+		100MG	N018240	002		Feb CAHN
<u>ATENOLOL; CHLORTHALIDONE</u>							
TABLET;ORAL							
TENORETIC 100							
AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
TENORETIC 50							
AB		ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN
<u>ATORVASTATIN CALCIUM</u>							
TABLET;ORAL							
ATORVASTATIN CALCIUM							
AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB			EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB			EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB			EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB		SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB			EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB			EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB			EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

>D> ATORVASTATIN CALCIUM; EZETIMIBE
 >D> TABLET;ORAL
 >D> LIPTRUZET
 >D> MERCK SHARP DOHME EQ 10MG BASE;10MG N200153 001 May 03, 2013 May DISC
 >A> @ EQ 10MG BASE;10MG N200153 001 May 03, 2013 May DISC
 >D> EQ 20MG BASE;10MG N200153 002 May 03, 2013 May DISC
 >A> @ EQ 20MG BASE;10MG N200153 002 May 03, 2013 May DISC
 >D> EQ 40MG BASE;10MG N200153 003 May 03, 2013 May DISC
 >A> @ EQ 40MG BASE;10MG N200153 003 May 03, 2013 May DISC
 >D> + EQ 80MG BASE;10MG N200153 004 May 03, 2013 May DISC
 >A> @ EQ 80MG BASE;10MG N200153 004 May 03, 2013 May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
 AB GLENMARK GENERICS 62.5MG;25MG A091211 002 Apr 06, 2015 Mar NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION
 ATRACURIUM BESYLATE
 AP AUROBINDO PHARMA LTD 10MG/ML A206011 001 Apr 08, 2015 Mar NEWA
 ATRACURIUM BESYLATE PRESERVATIVE FREE
 AP AUROBINDO PHARMA LTD 10MG/ML A206010 001 Apr 08, 2015 Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC
 ATROPINE SULFATE
 >D> AKORN 1% N206289 001 Jul 18, 2014 May CRLD
 >A> + 1% N206289 001 Jul 18, 2014 May CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL
 MOTOFEN
 + SEBELA IRELAND LTD 0.025MG;1MG N017744 002 Feb CAHN
 MOTOFEN HALF-STRENGTH
 @ SEBELA IRELAND LTD 0.025MG;0.5MG N017744 001 Feb CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)
 AVYCAZ
 + CEREXA INC EQ 0.5GM BASE;2GM/VIAL N206494 001 Feb 25, 2015 Feb NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL
 AZITHROMYCIN
 >A> AB LUPIN LTD EQ 100MG BASE/5ML A065488 001 May 15, 2015 May NEWA
 >A> AB EQ 200MG BASE/5ML A065488 002 May 15, 2015 May NEWA
 TABLET;ORAL
 AZITHROMYCIN
 >A> AB LUPIN LTD EQ 250MG BASE A065398 001 May 15, 2015 May NEWA
 >A> AB EQ 500MG BASE A065399 001 May 15, 2015 May NEWA
 >A> AB EQ 600MG BASE A065400 001 May 15, 2015 May NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL
 BENAZEPRIL HYDROCHLORIDE
 AB AMNEAL PHARMS LLC 5MG A076820 001 Feb 03, 2006 Jan CAHN
 AB 10MG A076820 002 Feb 03, 2006 Jan CAHN
 AB 20MG A076820 003 Feb 03, 2006 Jan CAHN
 AB 40MG A076820 004 Feb 03, 2006 Jan CAHN
 AB SUN PHARM INDS LTD 5MG A076344 001 Feb 11, 2004 Apr CAHN
 AB 10MG A076344 002 Feb 11, 2004 Apr CAHN
 AB 20MG A076344 003 Feb 11, 2004 Apr CAHN
 AB 40MG A076344 004 Feb 11, 2004 Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
 AB SUN PHARM INDS LTD 5MG;6.25MG A077483 001 Sep 08, 2005 Apr CAHN
 AB 10MG;12.5MG A077483 002 Sep 08, 2005 Apr CAHN
 AB 20MG;12.5MG A077483 003 Sep 08, 2005 Apr CAHN

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
 AB 20MG;25MG A 077483 004 Sep 08, 2005 Apr CAHN

BENZONATATE

CAPSULE;ORAL

BENZONATATE
 AA APOTEX INC 100MG A 091310 001 Jan 16, 2015 Jan NEWA
 AA 200MG A 091310 002 Jan 16, 2015 Jan NEWA
 AA BANNER LIFE SCIENCES 100MG A 081297 001 Jan 29, 1993 Jan CAHN
 AA 200MG A 081297 002 Oct 30, 2007 Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ONEXTON
 + DOW PHARM 3.75%;EQ 1.2% BASE N 050819 002 Nov 24, 2014 Jan CRLD

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE
 AA NUVO PHARM INC 0.5MG A 204713 001 Apr 14, 2015 Mar NEWA
 AA 1MG A 204713 002 Apr 14, 2015 Mar NEWA
 AA 2MG A 204713 003 Apr 14, 2015 Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE
 AB G AND W LABS INC EQ 0.05% BASE A 071467 001 Aug 10, 1987 Apr CAHN
 @ EQ 0.05% BASE A 071882 001 Jun 06, 1988 Apr CAHN

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETA-VAL
 AB G AND W LABS INC EQ 0.1% BASE A 070072 001 Jun 27, 1985 Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE
 AA HERITAGE PHARMA 5MG A 091256 001 May 04, 2010 Mar CAHN
 AA 10MG A 091256 002 May 04, 2010 Mar CAHN
 AA 25MG A 091256 003 May 04, 2010 Mar CAHN
 AA 50MG A 091256 004 May 04, 2010 Mar CAHN
 AA LANNETT HOLDINGS INC 5MG A 040703 001 Mar 27, 2008 Feb CMFD
 AA 50MG A 040677 001 Mar 27, 2008 Feb CMFD
 AA DUVOID
 AA WELLSRING PHARM 10MG A 086262 001 Jan CMFD
 >D> @ 25MG A 086263 001 May CMFD
 >A> AA 25MG A 086263 001 May CMFD
 >D> @ 50MG A 085882 003 May CMFD
 >A> AA 50MG A 085882 003 May CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE
 @ BANNER LIFE SCIENCES 75MG A 203174 001 Aug 12, 2014 Jan CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE
 >A> AB APOTEX INC 50MG A 200274 001 May 21, 2015 May NEWA
 >A> AB STASON PHARMS 50MG A 091011 001 Jun 10, 2015 May NEWA

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST
 AT ALCON RES LTD 0.03% A 202565 001 May 05, 2015 Apr NEWA
 AT + LUPIN LTD 0.03% A 203991 001 Feb 20, 2015 Apr CTEC
 + 0.03% A 203991 001 Feb 20, 2015 Mar CTEC
 AT + 0.03% A 203991 001 Feb 20, 2015 Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC
BROMDAY

>D>	AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May	CTEC
>A>	AT2	+		EQ 0.09% ACID	N021664	002	Oct 16, 2010	May	CTEC
BROMFENAC SODIUM									
>D>	AT		APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May	CTEC
>A>	AT2			EQ 0.09% ACID	A202620	001	Jun 23, 2014	May	CTEC
>D>	AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May	CRLD
>A>	AT1	+		EQ 0.09% ACID	A201211	001	May 11, 2011	May	CRLD
>D>	AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
>A>	AT2			EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
	AT1		PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan	NEWA

BUDESONIDE

AEROSOL, FOAM;RECTAL
UCERIS

+ VALEANT PHARMS INTL 2MG/ACTUATION
SPRAY, METERED;NASAL
BUDESONIDE

			APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC
--	--	--	------------	-------------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB			ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb	NEWA
AB				EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb	NEWA
AB			MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb	NEWA
AB				EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb	NEWA
>A>	AB		SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May	NEWA
>A>	AB			EQ 8MG BASE	A090279	002	Jun 10, 2015	May	NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
APLENZIN

			VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
				348MG	N022108	002	Apr 23, 2008	Feb	CAHN
		+		522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>A>	AB1		PRINSTON INC	100MG	A202304	001	May 26, 2015	May	NEWA
>A>	AB1			150MG	A202304	002	May 26, 2015	May	NEWA
>A>	AB1			200MG	A202304	003	May 26, 2015	May	NEWA
	AB2		SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar	CAHN
>D>	AB1		WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May	DISC
>A>		@		100MG	A201331	001	Aug 30, 2012	May	DISC
>D>	AB1			150MG	A201331	002	Aug 30, 2012	May	DISC
>A>		@		150MG	A201331	002	Aug 30, 2012	May	DISC
>D>	AB1			200MG	A201331	003	Aug 30, 2012	May	DISC
>A>		@		200MG	A201331	003	Aug 30, 2012	May	DISC

BUTABARBITAL SODIUM

TABLET;ORAL
BUTISOL SODIUM

>D>		+	MEDA PHARMS	50MG	N000793	003		May	DISC
>A>		@		50MG	N000793	003		May	DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL
BUTOCONAZOLE NITRATE

>A>		@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May	CTNA
>D>			GYNAZOLE-1						
>D>		@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May	CTNA

CALCIPOTRIENE

CREAM; TOPICAL
CALCIPOTRIENE

>A> AB GLENMARK PHARMS LTD 0.005% A205772 001 Jun 09, 2015 May NEWA

CALCITONIN SALMON

INJECTABLE; INJECTION
CALCITONIN-SALMON

@ IGI LABS INC 200 IU/ML A073690 001 Apr 14, 1995 Mar CAHN

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL

AB BANNER LIFE SCIENCES 0.25MCG A091174 001 May 24, 2013 Jan CAHN
 AB 0.5MCG A091174 002 May 24, 2013 Jan CAHN
 AB STRIDES PHARMA 0.25MCG A091356 001 Dec 12, 2014 Jan CAHN
 AB 0.5MCG A091356 002 Dec 12, 2014 Jan CAHN

CALCIUM ACETATE

TABLET; ORAL
CALCIUM ACETATE

AB ZYDUS PHARMS USA INC EQ 169MG CALCIUM A202885 001 Jan 22, 2015 Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML) N021703 010 Oct 10, 2008 Jan CPOT

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML) N021703 012 Oct 10, 2008 Jan CPOT

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML) N021703 011 Oct 10, 2008 Jan CPOT

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML) N021703 013 Oct 10, 2008 Jan CPOT

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 006 Oct 25, 2006 Jan CPOT

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 002 Oct 25, 2006 Jan CPOT

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 003 Oct 25, 2006 Jan CPOT

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 005 Oct 25, 2006 Jan CPOT

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 015 Oct 10, 2008 Jan CPOT

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML) N021703 004 Oct 25, 2006 Jan CPOT

INJECTABLE; INJECTION

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER		GM/1000ML (5000ML)					
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 0/0 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan	CPOT
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER							
+	GAMBRO RENAL PRODS	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan	CPOT
PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER							
@	GAMBRO RENAL PRODS	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan	CPOT

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	N/A/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan	NEWA
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	3.68GM/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan	NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER							
@	BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390	001		Mar	DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER							
@	BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML	N017438	001		Mar	DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb	CAIN
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
+	GAMBRO LUNDIA	3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Feb	CAIN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE							
AB	MACLEODS PHARMS LTD	16MG; 12.5MG	A204100	001	Feb 27, 2015	Feb	NEWA
AB		32MG; 12.5MG	A204100	002	Feb 27, 2015	Feb	NEWA
AB		32MG; 25MG	A204100	003	Feb 27, 2015	Feb	NEWA

CAPECITABINE

TABLET; ORAL
CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr	NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr	NEWA

CAPTOPRIL

TABLET; ORAL

>D>	CAPOTEN						
>D>	AB	PAR PHARM	12.5MG	N018343	005	Jan 17, 1985	May DISC
>A>		@	12.5MG	N018343	005	Jan 17, 1985	May DISC
>D>	AB		25MG	N018343	002		May DISC
>A>		@	25MG	N018343	002		May DISC
>D>	AB		50MG	N018343	001		May DISC
>A>		@	50MG	N018343	001		May DISC
>D>	AB	+	100MG	N018343	003		May DISC
>A>		@	100MG	N018343	003		May DISC
	CAPTOPRIL						
	@ G AND W LABS INC	12.5MG	A074462	001	Feb 13, 1996	Apr	CAHN
	@	12.5MG	A074590	004	Aug 30, 1996	Apr	CAHN
	@	25MG	A074462	002	Feb 13, 1996	Apr	CAHN
	@	25MG	A074590	002	Aug 30, 1996	Apr	CAHN
	@	50MG	A074462	003	Feb 13, 1996	Apr	CAHN
	@	50MG	A074590	001	Aug 30, 1996	Apr	CAHN
	@	100MG	A074462	004	Feb 13, 1996	Apr	CAHN
	@	100MG	A074590	003	Aug 30, 1996	Apr	CAHN
>D>	AB	MYLAN	100MG	A074434	004	Feb 13, 1996	May CRLD
>A>	AB	+	100MG	A074434	004	Feb 13, 1996	May CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr	CAHN
AB		25MG;25MG	A074827	002	Dec 29, 1997	Apr	CAHN
AB		50MG;15MG	A074827	004	Dec 29, 1997	Apr	CAHN
AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

>A>	AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
>A>	AB		200MG	A076697	002	May 20, 2011	May CAHN
>A>	AB		300MG	A076697	003	May 20, 2011	May CAHN
>D>	AB	NOSTRUM	100MG	A076697	001	May 20, 2011	May CAHN
>D>	AB		200MG	A076697	002	May 20, 2011	May CAHN
>D>	AB		300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL
RYTARY

	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	Jan	NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan	NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan	NEWA
	+	61.25MG;245MG	N203312	004	Jan 07, 2015	Jan	NEWA

SUSPENSION; ENTERAL
DUOPA

	+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan	NEWA
--	---	------------	-------------------	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

>A>	+	MYLAN PHARMS INC	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	May CAHN
>A>	AP		50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May CAHN
>A>	AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May CAHN
>A>	AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May CAHN
>A>	AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May CAHN
>D>	+	ONCO THERAPIES LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	May CAHN
>D>	AP		50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May CAHN
>D>	AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May CAHN
>D>	AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May CAHN
>D>	AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May CAHN

CARVEDILOL

TABLET; ORAL

CARVEDILOL

AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr	CAHN
AB		6.25MG	A076989	002	Sep 05, 2007	Apr	CAHN
AB		12.5MG	A076989	003	Sep 05, 2007	Apr	CAHN
AB		25MG	A076989	004	Sep 05, 2007	Apr	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr	CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr	CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan	CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan	CAHN

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr	NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr	NEWA
AB	SUPRAX						
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr	CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr	CFTG

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

>D>	@ ASTRAZENECA	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May	CAHN
>D>	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May	CAHN
>A>	@ IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May	CAHN
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar	CAHN
>A>	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May	CAHN
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar	CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar	CAHN
	CEFOTAN IN PLASTIC CONTAINER						
	@ IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar	CAHN
	@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr	CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr	CAHN

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr	CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr	CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan	CAHN
----	-------------	-------------------	---------	-----	--------------	-----	------

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

@ FACTA FARMA

@

EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan	CAHN
EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan	CAHN

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr	CAHN
AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr	CAHN

TABLET;ORAL

CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr	CAHN
AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr	CAHN
AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr	CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan	CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFUROXIME SODIUM

AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan	CAHN
----	-------------	--------------------	---------	-----	--------------	-----	------

CELECOXIB

CAPSULE;ORAL
CELECOXIB

>A>	AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May	NEWA
>A>	AB		100MG	A204197	002	Jun 02, 2015	May	NEWA
>A>	AB		200MG	A204197	003	Jun 02, 2015	May	NEWA
>A>	AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May	NEWA
>A>	AB		200MG	A202240	003	Jun 09, 2015	May	NEWA
>A>	AB		400MG	A202240	004	Jun 09, 2015	May	NEWA
	AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan	NEWA
	AB		200MG	A078857	003	Feb 11, 2015	Jan	NEWA
	AB		400MG	A078857	004	Feb 11, 2015	Jan	NEWA
	AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan	NEWA
	AB		100MG	A200562	002	Feb 11, 2015	Jan	NEWA
	AB		200MG	A200562	003	Feb 11, 2015	Jan	NEWA
	AB		400MG	A200562	004	Feb 11, 2015	Jan	NEWA

CEPHALEXIN

CAPSULE;ORAL
CEPHALEXIN

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr	CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr	CAHN

FOR SUSPENSION;ORAL
CEPHALEXIN

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr	CAHN
@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr	CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
CHLOROTHIAZIDE SODIUM

>A>	AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May	NEWA
-----	----	---------------	--------------------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan	NEWA
----	-----------------	-----------------	---------	-----	--------------	-----	------

VITUZ

AA	+ CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan	CFTG
----	-----------------	-----------------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR

+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr	NEWA
---	-----------------	--------------------------------------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHLORPROMAZINE HYDROCHLORIDE

+	EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb	CAHN
---	--------------------	---------	---------	-----	--	-----	------

TABLET;ORAL
CHLORPROMAZINE HYDROCHLORIDE

>D>	BP	SANDOZ	10MG	A080439	001		May	DISC
>A>	@		10MG	A080439	001		May	DISC
>D>	BP		25MG	A080439	002		May	DISC
>A>	@		25MG	A080439	002		May	DISC
>D>	BP		50MG	A080439	003		May	DISC
>A>	@		50MG	A080439	003		May	DISC

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>D>	BP	+	100MG	A080439	004		May	DISC
>A>		@	100MG	A080439	004		May	DISC
>D>	BP		200MG	A080439	005		May	DISC
>A>		@	200MG	A080439	005		May	DISC

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

		@ G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr	CAHN
AB		MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar	CMFD

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

		ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar	NEWA
+			250MG	N205750	002	Mar 17, 2015	Mar	NEWA
		RTRX	50MG	N205750	001	Mar 17, 2015	Apr	CAHN
+			250MG	N205750	002	Mar 17, 2015	Apr	CAHN

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

>D>	AP		MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May	CRLD
>A>	AP	+		EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May	CRLD
>D>			VISTIDE						
>D>	AP	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May	DISC
>A>		@		EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

		@ G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr	CAHN
--	--	--------------------	-------------------	---------	-----	--------------	-----	------

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

AP		CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr	CAHN
AP			400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr	CAHN
			CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr	CAHN
AP			400MG/200ML	A078024	002	Mar 18, 2008	Apr	CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr	CAHN
AB			EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr	CAHN
AB			EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr	CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb	NEWA
			CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb	NEWA
AP			EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb	NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB		G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	CAHN
AB			EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	CAHN
AB			EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	CAHN

CLADRIBINEINJECTABLE; INJECTION
CLADRIBINE

>A>	AP	MYLAN PHARMS INC	1MG/ML	A200510	001	Oct 06, 2011	May	CAHN
>D>	AP	ONCO THERAPIES LTD	1MG/ML	A200510	001	Oct 06, 2011	May	CAHN

CLARITHROMYCINFOR SUSPENSION; ORAL
CLARITHROMYCIN

AB		SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr	CAHN
AB			250MG/5ML	A065382	002	Aug 30, 2007	Apr	CAHN

TABLET; ORAL

CLARITHROMYCIN

AB		SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr	CAHN
AB			500MG	A065174	002	Sep 24, 2004	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

@ ABBVIE

500MG

N050775 001 Mar 03, 2000 Jan DISC

CLARITHROMYCIN

AB	+	TEVA	500MG	A065154	001	May 18, 2005	Jan	CRLD
----	---	------	-------	---------	-----	--------------	-----	------

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

>D>	+	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May	DISC
>A>	@		EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May	DISC
>D>			EQ 100MG BASE/VIAL; EQ 3GM	A062691	001	Dec 19, 1986	May	DISC
>A>	@		BASE/VIAL					
>A>	@		EQ 100MG BASE/VIAL; EQ 3GM	A062691	001	Dec 19, 1986	May	DISC
>D>	+		BASE/VIAL					
>D>	+		EQ 100MG BASE/VIAL; EQ 3GM	N050590	001	Apr 01, 1985	May	DISC
>A>	@		BASE/VIAL					
>A>	@		EQ 100MG BASE/VIAL; EQ 3GM	N050590	001	Apr 01, 1985	May	DISC
>D>	+		BASE/VIAL					
>D>	+		EQ 200MG BASE/VIAL; EQ 3GM	N050590	002	Apr 01, 1985	May	DISC
>A>	@		BASE/VIAL					
>A>	@		EQ 200MG BASE/VIAL; EQ 3GM	N050590	002	Apr 01, 1985	May	DISC
>D>			BASE/VIAL					
>D>	+	GLAXOSMITHKLINE	EQ 100MG BASE/100ML; EQ 3GM	N050658	001	Dec 15, 1989	May	DISC
>A>	@		BASE/100ML					
>A>	@		EQ 100MG BASE/100ML; EQ 3GM	N050658	001	Dec 15, 1989	May	DISC
			BASE/100ML					

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB		G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	CAHN
AB			EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	CAHN
AB		SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr	CAHN
AB			EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr	CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

@ IGI LABS INC

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989 Mar CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ BOCA PHARMA LLC

EQ 1% BASE

A062944 001 Jan 11, 1989 Jan CAHN

>A>	AT	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May	NEWA
-----	----	----------------	------------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

>D>	AB2	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May	CRLD
>A>	AB2	+	0.05%	A075430	001	May 26, 1999	May	CRLD
>D>		TEMOVATE E						
>D>	AB2	+	FOUGERA PHARMS	N020340	001	Jun 17, 1994	May	DISC
>A>		@	0.05%	N020340	001	Jun 17, 1994	May	DISC
>D>	AB	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May	CRLD

GEL;TOPICAL
 CLOBETASOL PROPIONATE
 >A> AB + 0.05% A 075368 001 Feb 15, 2000 May CRLD
 >D> TEMOVATE
 >D> AB + FOUGERA PHARMS 0.05% N 020337 001 Apr 29, 1994 May DISC
 >A> @ 0.05% N 020337 001 Apr 29, 1994 May DISC

OINTMENT;TOPICAL
 CLOBETASOL PROPIONATE
 AB G AND W LABS INC 0.05% A 074089 001 Feb 16, 1994 Feb CAHN
 SOLUTION;TOPICAL
 CLOBETASOL PROPIONATE
 AT G AND W LABS INC 0.05% A 074331 001 Dec 15, 1995 Mar CMFD

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL
 CLONIDINE
 AB ACTAVIS LABS UT INC 0.1MG/24HR A 090873 001 May 06, 2014 Mar CAHN
 AB 0.2MG/24HR A 090873 002 May 06, 2014 Mar CAHN
 AB 0.3MG/24HR A 090873 003 May 06, 2014 Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL
 CLONIDINE HYDROCHLORIDE
 >D> AB DAVA PHARMS INC 0.1MG A 071783 001 Apr 05, 1988 May DISC
 >A> @ 0.1MG A 071783 001 Apr 05, 1988 May DISC
 >D> AB 0.2MG A 071784 001 Apr 05, 1988 May DISC
 >A> @ 0.2MG A 071784 001 Apr 05, 1988 May DISC
 >D> AB 0.3MG A 071785 001 Apr 05, 1988 May DISC
 >A> @ 0.3MG A 071785 001 Apr 05, 1988 May DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE
 >A> AB2 ACTAVIS ELIZABETH 0.1MG A 202792 001 May 15, 2015 May NEWA
 >A> AB1 0.1MG A 203320 001 May 15, 2015 May NEWA
 >A> AB2 0.2MG A 202792 002 May 15, 2015 May NEWA
 >A> AB1 0.2MG A 203320 002 May 15, 2015 May NEWA
 >D> AB ANCHEN PHARMS 0.1MG A 202983 001 Apr 02, 2014 May CTEC
 >A> AB2 0.1MG A 202983 001 Apr 02, 2014 May CTEC
 >D> AB 0.2MG A 202983 002 Apr 02, 2014 May CTEC
 >A> AB2 0.2MG A 202983 002 Apr 02, 2014 May CTEC
 CLONIDINE HYDROCHLORIDE
 >D> AB ANCHEN PHARMS 0.1MG A 202984 001 Sep 30, 2013 May CTEC
 >A> AB1 0.1MG A 202984 001 Sep 30, 2013 May CTEC
 >D> AB 0.2MG A 202984 002 Sep 30, 2013 May CTEC
 >A> AB1 0.2MG A 202984 002 Sep 30, 2013 May CTEC
 KAPVAY
 >D> AB + CONCORDIA PHARMS INC 0.1MG N 022331 003 Sep 28, 2010 May CTEC
 >A> AB1 + 0.1MG N 022331 003 Sep 28, 2010 May CTEC
 >D> AB 0.2MG N 022331 004 Sep 28, 2010 May CTEC
 >A> AB1 0.2MG N 022331 004 Sep 28, 2010 May CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL
 CLORAZEPATE DIPOTASSIUM
 AB SUN PHARM INDS LTD 3.75MG A 076911 001 Sep 29, 2004 Apr CAHN
 AB 7.5MG A 076911 002 Sep 29, 2004 Apr CAHN
 AB 15MG A 076911 003 Sep 29, 2004 Apr CAHN

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL
 PREZCOBIX
 + JANSSEN PRODS 150MG;EQ 800MG BASE N 205395 001 Jan 29, 2015 Jan NEWA

CODEINE SULFATE

SOLUTION;ORAL
 CODEINE SULFATE
 @ ROXANE 30MG/5ML N 202245 001 Jun 30, 2011 Jan DISC

COLCHICINE

CAPSULE;ORAL
MITIGARE

HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014 Jan CAHN

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION
COLISTIMETHATE SODIUM

>A> AP XELLIA PHARMS APS EQ 150MG BASE/VIAL A205356 001 May 29, 2015 May NEWA

CYANOCOBALAMIN

INJECTABLE;INJECTION
CYANOCOBALAMIN

@ EUROHLTH INTL SARL 1MG/ML A080515 002 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB SUN PHARM INDS LTD 5MG A078722 001 May 12, 2008 Apr CAHN
AB 7.5MG A078722 002 May 12, 2008 Apr CAHN
AB 10MG A078722 003 May 12, 2008 Apr CAHN

CYTARABINE

INJECTABLE;INJECTION
CYTARABINE

>A> AP MYLAN PHARMS INC 20MG/ML A200915 001 Dec 13, 2011 May CAHN
>A> AP 20MG/ML A200916 001 Dec 13, 2011 May CAHN
>D> AP ONCO THERAPIES LTD 20MG/ML A200915 001 Dec 13, 2011 May CAHN
>D> AP 20MG/ML A200916 001 Dec 13, 2011 May CAHN

DABRAFENIB MESYLATE

CAPSULE;ORAL
TAFINLAR

NOVARTIS PHARMS CORP EQ 50MG BASE N202806 001 May 29, 2013 Mar CAHN
+ EQ 75MG BASE N202806 002 May 29, 2013 Mar CAHN

DALTEPARIN SODIUM

INJECTABLE;INJECTION
FRAGMIN

@ PHARMACIA AND UPJOHN 7,500 IU/0.75ML N020287 008 Apr 04, 2002 Apr CAHN

INJECTABLE;SUBCUTANEOUS
FRAGMIN

PHARMACIA AND UPJOHN 2,500IU/0.2ML (12,500IU/ML) N020287 001 Dec 22, 1994 Apr CAHN
5,000IU/0.2ML (25,000IU/ML) N020287 003 Mar 18, 1996 Apr CAHN
7,500IU/0.3ML (25,000IU/ML) N020287 005 Apr 04, 2002 Apr CAHN
@ 10,000IU/0.4ML (25,000IU/ML) N020287 002 May 01, 2007 Apr CAHN
10,000IU/ML (10,000IU/ML) N020287 004 Jan 30, 1998 Apr CAHN
12,500IU/0.5ML (25,000IU/ML) N020287 009 May 01, 2007 Apr CAHN
15,000IU/0.6ML (25,000IU/ML) N020287 010 May 01, 2007 Apr CAHN
18,000IU/0.72ML (25,000IU/ML) N020287 011 May 01, 2007 Apr CAHN
+ 95,000IU/3.8ML (25,000IU/ML) N020287 006 Apr 04, 2002 Apr CAHN
@ 95,000IU/9.5ML (10,000IU/ML) N020287 007 Apr 04, 2002 Apr CAHN

DANTROLENE SODIUM

CAPSULE;ORAL
DANTROLENE SODIUM

>A> AB ELITE LABS INC 25MG A076686 001 Oct 24, 2005 May CAHN
>A> AB 50MG A076686 002 Oct 24, 2005 May CAHN
>A> AB 100MG A076686 003 Oct 24, 2005 May CAHN
>D> AB MIKAH PHARMA 25MG A076686 001 Oct 24, 2005 May CAHN
>D> AB 50MG A076686 002 Oct 24, 2005 May CAHN
>D> AB 100MG A076686 003 Oct 24, 2005 May CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

AB ANCHEN PHARMS EQ 7.5MG BASE A091190 001 Mar 13, 2015 Mar NEWA
AB EQ 15MG BASE A091190 002 Mar 13, 2015 Mar NEWA
AB ENABLEX
AB WARNER CHILCOTT LLC EQ 7.5MG BASE N021513 001 Dec 22, 2004 Mar CFTG
AB + EQ 15MG BASE N021513 002 Dec 22, 2004 Mar CFTG

DECITABINE

INJECTABLE; INTRAVENOUS
 DACOGEN
 AP + OTSUKA PHARM CO LTD 50MG/VIAL N021790 001 May 02, 2006 Jan CAHN

DEFERASIROX

TABLET; ORAL
 JADENU
 NOVARTIS PHARMS CORP 90MG N206910 001 Mar 30, 2015 Mar NEWA
 180MG N206910 002 Mar 30, 2015 Mar NEWA
 + 360MG N206910 003 Mar 30, 2015 Mar NEWA

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS
 KYBELLA
 + KYTHERA BIOPHARMS 20MG/2ML (10MG/ML) N206333 001 Apr 29, 2015 Apr NEWA

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
 IPRIVASK
 >D> + MARATHON PHARMS LLC 15MG/VIAL N021271 001 Apr 04, 2003 May CAHN
 >A> + VALEANT PHARMS NORTH 15MG/VIAL N021271 001 Apr 04, 2003 May CAHN

DESMOPRESSIN ACETATE

TABLET; ORAL
 DDAVP
 AB FERRING PHARMS INC 0.1MG N019955 001 Sep 06, 1995 Jan CAHN
 AB + 0.2MG N019955 002 Sep 06, 1995 Jan CAHN
 DESMOPRESSIN ACETATE
 >A> AB GLENMARK PHARMS LTD 0.1MG A201831 001 May 28, 2015 May NEWA
 >A> AB 0.2MG A201831 002 May 28, 2015 May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
 DESOGESTREL AND ETHINYL ESTRADIOL
 >A> AB FAMY CARE LTD 0.15MG; 0.03MG A202085 001 May 20, 2015 May NEWA
 KARIVA
 AB + BARR 0.15MG, N/A; 0.02MG, 0.01MG A075863 001 Apr 05, 2002 Apr CTEC
 KIMIDESS
 AB VINTAGE PHARMS 0.15MG, N/A; 0.02MG, 0.01MG A076681 001 Apr 30, 2015 Apr NEWA

DESONIDE

CREAM; TOPICAL
 DESONIDE
 >D> @ TEVA PHARMS 0.05% A074027 001 Sep 28, 1992 May CMFD
 >A> AB 0.05% A074027 001 Sep 28, 1992 May CMFD

DESOXIMETASONE

OINTMENT; TOPICAL
 DESOXIMETASONE
 AB PERRIGO NEW YORK 0.25% A077770 001 Apr 20, 2015 Apr NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 DEXAMETHASONE SODIUM PHOSPHATE
 @ EUROHLTH INTL SARL EQ 4MG PHOSPHATE/ML A084282 001 Mar CAHN
 AP + EQ 10MG PHOSPHATE/ML A087702 001 Sep 07, 1982 Feb CAHN
 AP MYLAN PHARMS INC EQ 4MG PHOSPHATE/ML A040803 001 Aug 29, 2008 Apr CAHN
 AP EQ 10MG PHOSPHATE/ML A040802 001 Aug 29, 2008 Apr CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
 MAXITROL
 AT + ALCON LABS INC 0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM N050065 002 Mar CAHN
 SUSPENSION/DROPS; OPHTHALMIC
 MAXITROL
 AT + ALCON LABS INC 0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML N050023 002 Mar CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
PRECEDEX

HOSPIRA EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) N021038 004 Nov 14, 2014 Jan NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETH W/ DEXTROMETHORPHAN

>D> @ ACTAVIS MID ATLANTIC 15MG/5ML; 6.25MG/5ML A088762 001 Oct 31, 1984 May CAHN
>A> @ G AND W LABS INC 15MG/5ML; 6.25MG/5ML A088762 001 Oct 31, 1984 May CAHN

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5GM/100ML; 30MG/100ML; 37MG/100ML; 36 8MG/100ML; 526MG/100ML; 502MG/100ML N017451 001 Mar DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION
MD-76R

AP + LIEBEL-FLARSHEIM 66%; 10% N019292 001 Sep 29, 1989 Feb CAHN

SOLUTION; ORAL, RECTAL
MD-GASTROVIEW

AA LIEBEL-FLARSHEIM 66%; 10% A087388 001 Jan CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
TENUATE

AA + ACTAVIS LABS UT INC 25MG N011722 002 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL
TENUATE DOSPAN

AB + ACTAVIS LABS UT INC 75MG N012546 001 Mar CAHN

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

AB HERITAGE PHARMA 500MG A202845 001 Mar 08, 2012 Mar CAHN

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN

AP EUROHLTH INTL SARL 0.25MG/ML A083391 001 Feb CAHN

TABLET; ORAL
DIGOXIN

AB MYLAN PHARMS INC 0.125MG A040282 001 Dec 23, 1999 Jan CTEC
AB 0.25MG A040282 002 Dec 23, 1999 Jan CTEC
AB SUN PHARM INDS INC 0.125MG A076363 001 Jan 31, 2003 Feb CMFD
AB 0.25MG A076363 002 Jan 31, 2003 Feb CMFD

LANOXIN

AB CONCORDIA PHARMS INC 0.0625MG N020405 001 Sep 30, 1997 Apr CAHN
0.125MG N020405 002 Sep 30, 1997 Apr CAHN
0.1875MG N020405 003 Sep 30, 1997 Apr CAHN
AB + 0.25MG N020405 004 Sep 30, 1997 Apr CAHN
@ 0.375MG N020405 005 Sep 30, 1997 Apr CAHN
@ 0.5MG N020405 006 Sep 30, 1997 Apr CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILACOR XR

@ ACTAVIS LABS UT INC 120MG N020092 001 May 29, 1992 Mar CAHN
@ 180MG N020092 002 May 29, 1992 Mar CAHN
@ 240MG N020092 003 May 29, 1992 Mar CAHN
@ WATSON LABS 120MG N020092 001 May 29, 1992 Feb DISC
@ 180MG N020092 002 May 29, 1992 Feb DISC
@ 240MG N020092 003 May 29, 1992 Feb DISC

DILTIAZEM HYDROCHLORIDE

AB2 + MYLAN 240MG A075124 001 Mar 18, 1998 Feb CRLD
TIAZAC
AB4 VALEANT PHARMS NORTH 120MG N020401 001 Sep 11, 1995 Feb CAHN

CAPSULE, EXTENDED RELEASE;ORAL
TIAZAC

AB4		180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4		240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4		300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4		360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+	420MG	N020401	006	Oct 16, 1998	Feb	CAHN

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE
@ MYLAN PHARMS INC

5MG/ML	A075375	001	Sep 30, 1999	Apr	CAHN
--------	---------	-----	--------------	-----	------

DIPYRIDAMOLE

INJECTABLE; INJECTION
DIPYRIDAMOLE
@ MYLAN PHARMS INC

5MG/ML	A075769	001	Nov 27, 2002	Apr	CAHN
--------	---------	-----	--------------	-----	------

DISULFIRAM

TABLET; ORAL
DISULFIRAM

MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb	NEWA
AB	500MG	A203916	002	Mar 04, 2015	Feb	NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

>A> AB	AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May	NEWA
>A> AB		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May	NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE
@ IGI LABS INC

EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN
-------------------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB	HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan	NEWA
AB		10MG	A203034	002	Jan 30, 2015	Jan	NEWA
AB	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr	CAHN
AB		10MG	A076786	002	Nov 26, 2010	Apr	CAHN
>A> AB		23MG	A204293	001	Jun 05, 2015	May	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC

FOREST LABS LLC
+

10MG;14MG	N206439	001	Dec 23, 2014	Mar	CAHN
10MG;28MG	N206439	002	Dec 23, 2014	Mar	CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE

@ IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar	CAHN
@	40MG/ML	N018656	001	Jun 28, 1983	Mar	CAHN
@	80MG/ML	A070089	001	Oct 23, 1985	Mar	CAHN
@	80MG/ML	A070090	001	Oct 23, 1985	Mar	CAHN
@	80MG/ML	A070091	001	Oct 23, 1985	Mar	CAHN
@	160MG/ML	A070092	001	Oct 23, 1985	Mar	CAHN
@	160MG/ML	A070093	001	Oct 23, 1985	Mar	CAHN
@	160MG/ML	A070094	001	Oct 23, 1985	Mar	CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE; ORAL
DOXEPIIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD

CREAM; TOPICAL
ZONALON

+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN
---	-------------------	----	---------	-----	--------------	-----	------

DOXERCALCIFEROL

INJECTABLE; INJECTION
DOXERCALCIFEROL

AP AKORN INC 4MCG/2ML (2MCG/ML) A203929 001 May 07, 2015 Apr NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

>A> AP MYLAN PHARMS INC 2MG/ML A200901 001 Feb 14, 2012 May CAHN
 >A> AP 10MG/VIAL A200170 001 Oct 28, 2011 May CAHN
 >A> AP 50MG/VIAL A200170 002 Oct 28, 2011 May CAHN
 >D> AP ONCO THERAPIES LTD 2MG/ML A200901 001 Feb 14, 2012 May CAHN
 >D> AP 10MG/VIAL A200170 001 Oct 28, 2011 May CAHN
 >D> AP 50MG/VIAL A200170 002 Oct 28, 2011 May CAHN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

>A> AB NOVEL LABS INC EQ 50MG BASE A204446 001 May 28, 2015 May NEWA
 >A> AB EQ 75MG BASE A204446 002 May 28, 2015 May NEWA
 >A> AB EQ 100MG BASE A204446 003 May 28, 2015 May NEWA
 AB SUN PHARM INDS LTD EQ 50MG BASE A065053 001 Nov 22, 2000 Apr CAHN
 AB EQ 75MG BASE A065053 003 Sep 10, 2003 Apr CAHN
 AB EQ 100MG BASE A065053 002 Nov 22, 2000 Apr CAHN
 TABLET; ORAL
 DOXYCYCLINE
 AB SUN PHARM INDS LTD EQ 50MG BASE A065356 001 May 31, 2006 Apr CAHN
 AB EQ 75MG BASE A065356 002 May 31, 2006 Apr CAHN
 AB EQ 100MG BASE A065356 003 May 31, 2006 Apr CAHN

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

@ IGI LABS INC 2.5MG/ML A072019 001 Oct 19, 1988 Mar CAHN
 @ 2.5MG/ML A072020 001 Oct 19, 1988 Mar CAHN
 @ 2.5MG/ML A072021 001 Oct 19, 1988 Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL-28
DROSPIRENONE AND ETHINYL ESTRADIOL

AB FAMY CARE LTD 3MG;0.03MG A202131 001 May 04, 2015 Apr NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE

AB FOUGERA PHARMS 1% A076075 001 Nov 26, 2002 Mar CRLD
 AB + PERRIGO NEW YORK 1% A076479 001 Jun 23, 2004 Mar CRLD

EDOXABAN TOSYLATE

TABLET; ORAL
SAVAYSA

DAIICHI SANKYO EQ 15MG BASE N206316 001 Jan 08, 2015 Jan NEWA
 EQ 30MG BASE N206316 002 Jan 08, 2015 Jan NEWA
 + EQ 60MG BASE N206316 003 Jan 08, 2015 Jan NEWA

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON

+ MYLAN INSTITUTIONAL 10MG/ML A088873 001 Aug 06, 1985 Mar CRLD
 TENSILON
 @ IGI LABS INC 10MG/ML N007959 001 Apr CAHN
 @ VALEANT PHARMS 10MG/ML N007959 001 Mar DISC
 TENSILON PRESERVATIVE FREE
 @ IGI LABS INC 10MG/ML N007959 002 Apr CAHN
 @ VALEANT PHARMS 10MG/ML N007959 002 Mar DISC

ELTROMBOPAG OLAMINE

TABLET; ORAL
PROMACTA

		NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar	CAHN
			EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar	CAHN
>D>	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	May	CRLD
>A>			EQ 50MG ACID	N022291	002	Nov 20, 2008	May	CRLD
	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar	CAHN
>D>			EQ 75MG ACID	N022291	003	Sep 08, 2009	May	CRLD
>A>	+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May	CRLD
			EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar	CAHN
>D>			EQ 100MG ACID	N022291	005	Nov 16, 2012	May	CRLD
>A>	+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May	CRLD
			EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar	CAHN

>A> ELUXADOLINE

>A> TABLET; ORAL
>A> VIBERZI

>A>		FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May	NEWA
>A>	+		100MG	N206940	002	May 27, 2015	May	NEWA

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL
GLYXAMBI

		BOEHRINGER INGELHEIM	10MG; 5MG	N206073	001	Jan 30, 2015	Jan	NEWA
	+		25MG; 5MG	N206073	002	Jan 30, 2015	Jan	NEWA

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

AB		SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar	CMFD
AB			5MG	A075496	002	Aug 22, 2000	Mar	CMFD
AB			10MG	A075459	001	Aug 22, 2000	Mar	CMFD
AB			20MG	A075459	002	Aug 22, 2000	Mar	CMFD
	@	SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr	CAHN
	@		5MG	A075556	002	Aug 22, 2000	Apr	CAHN
	@		10MG	A075556	003	Aug 22, 2000	Apr	CAHN
	@		20MG	A075556	004	Aug 22, 2000	Apr	CAHN
		VASOTEC						
AB		VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr	CAHN
AB			5MG	N018998	001	Dec 24, 1985	Apr	CAHN
AB			10MG	N018998	002	Dec 24, 1985	Apr	CAHN
AB	+		20MG	N018998	003	Dec 24, 1985	Apr	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		G AND W LABS INC	5MG; 12.5MG	A075727	001	Sep 18, 2001	Apr	CAHN
AB			10MG; 25MG	A075727	002	Sep 18, 2001	Apr	CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

>A>	AP	MYLAN PHARMS INC	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	May	CAHN
>A>	AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	May	CAHN
>D>	AP	ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	May	CAHN
>D>	AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	May	CAHN

EPTIFIBATIDE

INJECTABLE; INJECTION
EPTIFIBATIDE

>A>	AP	TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015	May	NEWA
		INTEGRILIN						
>D>	+	SCHERING	75MG/100ML	N020718	002	May 18, 1998	May	CFTG
>A>	AP	+	75MG/100ML	N020718	002	May 18, 1998	May	CFTG

ERGOCALCIFEROL

CAPSULE;ORAL
 VITAMIN D
 AA BANNER LIFE SCIENCES 50,000 IU A080704 001 Jan CAHN

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL
 ERYTHROMYCIN ESTOLATE
 @ G AND W LABS INC EQ 125MG BASE/5ML A062169 001 Oct 17, 1990 Apr CAHN
 @ EQ 250MG BASE/5ML A062169 002 Oct 17, 1990 Apr CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL
 ESCITALOPRAM OXALATE
 >A> AA ANTRIM PHARMS LLC EQ 5MG BASE/5ML A203967 001 May 26, 2015 May NEWA
 TABLET;ORAL
 ESCITALOPRAM OXALATE
 AB MYLAN PHARMS INC EQ 5MG BASE A077550 001 May 14, 2015 Apr NEWA
 AB EQ 10MG BASE A077550 002 May 14, 2015 Apr NEWA
 AB EQ 20MG BASE A077550 003 May 14, 2015 Apr NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION
 ESMOLOL HYDROCHLORIDE
 AP LUITPOLD 10MG/ML A201126 001 Feb 20, 2015 Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL
 ESOMEPRAZOLE MAGNESIUM
 AB IVAX SUB TEVA PHARMS EQ 20MG BASE A078003 001 Jan 26, 2015 Jan NEWA
 AB EQ 40MG BASE A078003 002 Jan 26, 2015 Jan NEWA
 NEXIUM
 AB ASTRAZENECA PHARMS EQ 20MG BASE N021153 001 Feb 20, 2001 Jan CFTG
 AB + EQ 40MG BASE N021153 002 Feb 20, 2001 Jan CFTG

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL
 ALORA
 BX ACTAVIS LABS UT INC 0.025MG/24HR N020655 004 Apr 05, 2002 Mar CAHN
 BX 0.05MG/24HR N020655 001 Dec 20, 1996 Mar CAHN
 BX 0.075MG/24HR N020655 002 Dec 20, 1996 Mar CAHN
 BX 0.1MG/24HR N020655 003 Dec 20, 1996 Mar CAHN
 MINIVELLE
 NOVEN 0.025MG/24HR N203752 005 Sep 23, 2014 Jan NEWA
 TABLET;VAGINAL
 ESTRADIOL
 >A> @ AMNEAL PHARMS 10MCG A205256 001 May 29, 2015 May DISC

ESZOPICLONE

TABLET;ORAL
 ESZOPICLONE
 AB MACLEODS PHARMS LTD 1MG A202929 001 Jan 30, 2015 Jan NEWA
 AB 2MG A202929 002 Jan 30, 2015 Jan NEWA
 AB 3MG A202929 003 Jan 30, 2015 Jan NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL
 ETHAMBUTOL HYDROCHLORIDE
 AB VERSAPHARM INC 100MG A075095 001 Nov 30, 1999 Jan CMFD
 AB 400MG A075095 002 Nov 30, 1999 Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL
 ASHLYNA
 AB GLENMARK GENERICS 0.03MG,0.01MG;0.15MG,N/A A203163 001 Feb 23, 2015 Feb NEWA
 LEVONORGESTREL AND ETHINYL ESTRADIOL
 AB FAMY CARE LTD 0.03MG;0.15MG A200490 001 Apr 21, 2015 Apr NEWA
 AB GLENMARK GENERICS 0.02MG;0.09MG A202791 001 Apr 09, 2015 Mar NEWA
 AB + WATSON LABS 0.02MG;0.09MG A079218 001 Jun 06, 2011 Mar CTEC

<u>TABLET;ORAL</u>							
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL							
>A>	AB	FAMY CARE LTD	0.03MG,0.01MG;0.15MG,N/A	A200492	001	May 27, 2015	May NEWA
<u>TABLET;ORAL-28</u>							
VIENVA							
>A>	AB1	SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015	May NEWA
<u>ETHINYL ESTRADIOL; NORELGESTROMIN</u>							
FILM, EXTENDED RELEASE;TRANSDERMAL							
ORTHO EVRA							
@ JANSSEN PHARMS 0.035MG/24HR;0.15MG/24HR							
XULANE							
AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CRLD
<u>ETHINYL ESTRADIOL; NORETHINDRONE</u>							
TABLET;ORAL-21							
BREVICON 21-DAY							
@ ACTAVIS LABS UT INC 0.035MG;0.5MG							
NORINYL 1+35 21-DAY							
AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	001		Feb CAHN
TRI-NORINYL 21-DAY							
@ ACTAVIS LABS UT INC 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG							
N018977 001 Apr 13, 1984 Feb CAHN							
TABLET;ORAL-28							
BREVICON 28-DAY							
AB		ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001		Mar CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL							
AB		FAMY CARE LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr NEWA
NORINYL 1+35 28-DAY							
AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002		Feb CAHN
TRI-NORINYL 28-DAY							
AB	+	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Feb CAHN
TABLET, CHEWABLE;ORAL							
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB		FAMY CARE LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	Mar NEWA
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>							
TABLET;ORAL							
FEMHRT							
AB		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar CTEC
LARIN 24 FE							
AB		NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015	Feb NEWA
LOESTRIN 24 FE							
@ WARNER CHILCOTT 0.02MG;1MG							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar CTEC
AB		GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015	Mar NEWA
AB			0.005MG;1MG	A203038	002	Apr 02, 2015	Mar NEWA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	+	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jan CRLD
TABLET;ORAL-21							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB		FAMY CARE LTD	0.03MG;1.5MG	A202770	001	Feb 19, 2015	Feb NEWA
TABLET;ORAL-28							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB		FAMY CARE LTD	0.03MG;1.5MG	A202741	001	Feb 20, 2015	Feb NEWA
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>							
TABLET;ORAL-28							
NORGESTIMATE AND ETHINYL ESTRADIOL							
AB		OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG	A200383	001	Apr 07, 2015	Mar NEWA
AB			0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar NEWA
<u>ETHINYL ESTRADIOL; NORGESTREL</u>							
TABLET;ORAL-28							
LOW-OGESTREL-28							
AB		WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb CMFD

ETHOSUXIMIDECAPSULE;ORAL
ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan	CAHN
----	----------------------	-------	---------	-----	--------------	-----	------

ETOMIDATEINJECTABLE; INJECTION
ETOMIDATE

AP	MYLAN PHARMS INC	2MG/ML	A078289	001	Jan 02, 2009	Apr	CAHN
----	------------------	--------	---------	-----	--------------	-----	------

FAMOTIDINETABLET;ORAL
PEPCID

AB	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb	CAHN
AB	+	40MG	N019462	002	Oct 15, 1986	Feb	CAHN

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

>A>	AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May	NEWA
>A>	AB		5MG	A203032	002	May 21, 2015	May	NEWA
>A>	AB		10MG	A203032	003	May 21, 2015	May	NEWA
	AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr	CAHN
	AB		5MG	A091200	002	Dec 13, 2013	Apr	CAHN
	AB		10MG	A091200	003	Dec 13, 2013	Apr	CAHN

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr	CAHN
AB		130MG	A201748	002	Oct 31, 2014	Apr	CAHN

TABLET;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr	CAHN
		107MG	A076635	002	Oct 31, 2005	Apr	CAHN
AB		160MG	A076635	003	Oct 31, 2005	Apr	CAHN

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN

FENTANYL CITRATEFILM;BUCCAL
ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar	CAHN
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar	CAHN
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar	CAHN
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar	CAHN
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar	CAHN

INJECTABLE; INJECTION
FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN
----	---	--------------------	-------------------	---------	-----	--------------	-----	------

FENTANYL HYDROCHLORIDESYSTEM; IONTOPHORESIS, TRANSDERMAL
IONSYS

@	THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr	CAHN
---	------------------	---------	---------	-----	--------------	-----	------

FERRIC CITRATE

TABLET;ORAL
AURYXIA

+ KERYX BIOPHARMS EQ 210MG IRON N205874 001 Sep 05, 2014 Jan CTNA

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)
TRIFERIC

+ ROCKWELL MEDICAL INC 27.2MG IRON/5ML (5.44MG IRON/ML) N206317 001 Jan 23, 2015 Jan NEWA

FLECAINIDE ACETATE

TABLET;ORAL
FLECAINIDE ACETATE

AB ANI PHARMS INC 50MG A075882 001 Oct 28, 2002 Apr CAHN
 AB 100MG A075882 002 Oct 28, 2002 Apr CAHN
 AB 150MG A075882 003 Oct 28, 2002 Apr CAHN
 AB SUN PHARM INDS LTD 50MG A076421 001 Mar 28, 2003 Apr CAHN
 AB 100MG A076421 002 Mar 28, 2003 Apr CAHN
 AB 150MG A076421 003 Mar 28, 2003 Apr CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL
FLUCONAZOLE

AB SUN PHARM INDS LTD 50MG/5ML A076332 001 Jul 29, 2004 Apr CAHN
 AB 200MG/5ML A076332 002 Jul 29, 2004 Apr CAHN

INJECTABLE;INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A077988 001 May 26, 2010 Apr CAHN
 AP 400MG/200ML (2MG/ML) A077988 002 May 26, 2010 Apr CAHN
 @ MYLAN PHARMS INC 200MG/100ML (2MG/ML) A076888 001 Mar 25, 2005 Apr CAHN
 @ 400MG/200ML (2MG/ML) A076888 002 Mar 25, 2005 Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A077947 001 May 26, 2010 Apr CAHN
 AP 400MG/200ML (2MG/ML) A077947 002 May 26, 2010 Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

CLARIS PHARMASERVICE 100MG/50ML (2MG/ML) A077909 003 Apr 20, 2015 Apr NEWA
 100MG/50ML (2MG/ML) A077909 003 Apr 20, 2015 Apr CAHN
 AP 200MG/100ML (2MG/ML) A077909 001 May 26, 2010 Apr CAHN
 AP 400MG/200ML (2MG/ML) A077909 002 May 26, 2010 Apr CAHN
 @ MYLAN PHARMS INC 200MG/100ML (2MG/ML) A076889 001 Mar 25, 2005 Apr CAHN
 @ 400MG/200ML (2MG/ML) A076889 002 Mar 25, 2005 Apr CAHN

TABLET;ORAL

FLUCONAZOLE

>D> @ HARRIS PHARM 50MG A078423 001 Mar 07, 2011 May CMFD
 >A> AB 50MG A078423 001 Mar 07, 2011 May CMFD
 >D> @ 100MG A078423 002 Mar 07, 2011 May CMFD
 >A> AB 100MG A078423 002 Mar 07, 2011 May CMFD
 >D> @ 150MG A078423 003 Mar 07, 2011 May CMFD
 >A> AB 150MG A078423 003 Mar 07, 2011 May CMFD
 >D> @ 200MG A078423 004 Mar 07, 2011 May CMFD
 >A> AB 200MG A078423 004 Mar 07, 2011 May CMFD

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

>A> AP MYLAN PHARMS INC 50MG/2ML (25MG/ML) A200647 001 Dec 21, 2011 May CAHN
 >D> AP ONCO THERAPIES LTD 50MG/2ML (25MG/ML) A200647 001 Dec 21, 2011 May CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F 18

AP BIOMEDCL RES FDN 20-300mCi/ML A203710 001 May 01, 2015 Apr NEWA
 AP 20-300mCi/ML A203837 001 May 01, 2015 Apr NEWA
 UNIV NORTH DAKOTA 4-500mCi/ML A203994 001 Feb 04, 2015 Jan NEWA
 FLUDEOXYGLUCOSE F18
 AP METHODIST HOSP RES 20-300mCi/ML A203904 001 Apr 23, 2015 Apr NEWA
 PRECISION NUCLEAR 20-500mCi/ML A204546 001 Apr 07, 2015 Mar NEWA
 SPECTRON MRC LLC 4-500mCi/ML A203911 001 Apr 22, 2015 Apr NEWA

FLUMAZENIL

	INJECTABLE; INJECTION							
	FLUMAZENIL							
	@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)		A076755	002	Oct 12, 2004	Apr	CAHN
	@	1MG/10ML (0.1MG/ML)		A076755	001	Oct 12, 2004	Apr	CAHN
AP	MYLAN PHARMS INC	0.5MG/5ML (0.1MG/ML)		A078595	001	May 13, 2008	Apr	CAHN
AP	+	1MG/10ML (0.1MG/ML)		A078595	002	May 13, 2008	Apr	CAHN

FLUOCINONIDE

	GEL; TOPICAL							
	FLUOCINONIDE							
AB	G AND W LABS INC	0.05%		A072537	001	Feb 07, 1989	Apr	CAHN

FLUOROURACIL

	CREAM; TOPICAL							
	CARAC							
AB	+ VALEANT PHARMS NORTH	0.5%		N020985	001	Oct 27, 2000	Apr	CFTG
	+	0.5%		N020985	001	Oct 27, 2000	Feb	CAHN
	FLUOROURACIL							
AB	SPEAR PHARMS INC	0.5%		A203122	001	Apr 20, 2015	Apr	NEWA
	INJECTABLE; INJECTION							
	FLUOROURACIL							
AP	MYLAN PHARMS INC	1GM/20ML (50MG/ML)		A202668	002	Jul 17, 2012	Apr	CAHN
AP		500MG/10ML (50MG/ML)		A202668	001	Jul 17, 2012	Apr	CAHN

FLUOXETINE HYDROCHLORIDE

	CAPSULE; ORAL							
	FLUOXETINE HYDROCHLORIDE							
	@ ANI PHARMS INC	EQ 10MG BASE		A076287	001	May 20, 2008	Mar	DISC
	@	EQ 20MG BASE		A076287	002	May 20, 2008	Mar	DISC
	+ MYLAN	EQ 20MG BASE		A078045	002	Nov 17, 2008	Mar	CRLD
		EQ 20MG BASE		A078045	002	Nov 17, 2008	Mar	CTEC
	@ SANDOZ	EQ 10MG BASE		A077469	001	Nov 17, 2008	Mar	DISC
	@	EQ 20MG BASE		A077469	002	Nov 17, 2008	Mar	DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE		A204597	001	Mar 16, 2015	Mar	NEWA
AB1		EQ 20MG BASE		A204597	002	Mar 16, 2015	Mar	NEWA
AB		EQ 40MG BASE		A204597	003	Mar 16, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE		A076990	001	Dec 13, 2004	Apr	CAHN
	SARAFEM							
	@ ELI LILLY AND CO	EQ 10MG BASE		N018936	007	Jul 06, 2000	Mar	DISC
	@	EQ 20MG BASE		N018936	008	Jul 06, 2000	Mar	DISC

FLUPHENAZINE DECANOATE

	INJECTABLE; INJECTION							
	FLUPHENAZINE DECANOATE							
	@ MYLAN PHARMS INC	25MG/ML		A075918	001	Aug 17, 2001	Apr	CAHN

FLURANDRENOLIDE

	OINTMENT; TOPICAL							
	CORDRAN							
>D>	@ AQUA PHARMS	0.05%		N012806	001		May	CMFD
>A>		0.05%		N012806	001		May	CMFD
	TAPE; TOPICAL							
	CORDRAN							
	+ ACTAVIS LABS UT INC	0.004MG/SQ CM		N016455	001		Mar	CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

	POWDER; INHALATION							
	BREO ELLIPTA							
	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH		N204275	002	Apr 30, 2015	Apr	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

	TABLET; ORAL							
	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE							
AB	SUN PHARM INDS LTD	10MG;12.5MG		A076739	001	Dec 17, 2004	Apr	CAHN
AB		20MG;12.5MG		A076739	002	Dec 17, 2004	Apr	CAHN

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

@	IGI LABS INC	10MG/ML	A 070095	001	Sep 09, 1985	Mar	CAHN
@		10MG/ML	A 070096	001	Sep 09, 1985	Mar	CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A 076606	001	Oct 07, 2005	Apr	CAHN
AB		300MG	A 076606	002	Oct 07, 2005	Apr	CAHN
AB		400MG	A 076606	003	Oct 07, 2005	Apr	CAHN

GADOVERSETAMIDEINJECTABLE; INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	16.545GM/50ML (330.9MG/ML)	N 020975	001	Dec 08, 1999	Feb	CAHN
+		1654.5MG/5ML (330.9MG/ML)	N 020937	001	Dec 08, 1999	Feb	CAHN
+		3309MG/10ML (330.9MG/ML)	N 020937	002	Dec 08, 1999	Feb	CAHN
+		4963.5MG/15ML (330.9MG/ML)	N 020937	003	Dec 08, 1999	Feb	CAHN
+		6618MG/20ML (330.9MG/ML)	N 020937	004	Dec 08, 1999	Feb	CAHN
	OPTIMARK IN PLASTIC CONTAINER						
+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N 020976	002	Dec 08, 1999	Feb	CAHN
+		4963.5MG/15ML (330.9MG/ML)	N 020976	003	Dec 08, 1999	Feb	CAHN
+		6618MG/20ML (330.9MG/ML)	N 020976	004	Dec 08, 1999	Feb	CAHN
+		9927MG/30ML (330.9MG/ML)	N 020976	001	Dec 08, 1999	Feb	CAHN

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

>A>	AP	MYLAN PHARMS INC	EQ 1GM BASE/VIAL	A 200145	002	Jul 25, 2011	May	CAHN
>A>	AP		EQ 2GM BASE/VIAL	A 200145	003	Jul 25, 2011	May	CAHN
>A>	AP		EQ 200MG BASE/VIAL	A 200145	001	Jul 25, 2011	May	CAHN
>D>	AP	ONCO THERAPIES LTD	EQ 1GM BASE/VIAL	A 200145	002	Jul 25, 2011	May	CAHN
>D>	AP		EQ 2GM BASE/VIAL	A 200145	003	Jul 25, 2011	May	CAHN
>D>	AP		EQ 200MG BASE/VIAL	A 200145	001	Jul 25, 2011	May	CAHN

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N 020622	002	Feb 12, 2002	Mar	CFTG
AP		SANDOZ INC	20MG/ML	A 090218	001	Apr 16, 2015	Mar	NEWA

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

@	HIKMA PHARMS	1MG	A 078952	001	Aug 01, 2013	Apr	DISC
@		2MG	A 078952	002	Aug 01, 2013	Apr	DISC
@		4MG	A 078952	003	Aug 01, 2013	Apr	DISC

GLIPIZIDETABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

>A>	AB	MYLAN PHARMS INC	2.5MG	A 202298	001	May 19, 2015	May	NEWA
>A>	AB		5MG	A 202298	002	May 19, 2015	May	NEWA
>A>	AB		10MG	A 202298	003	May 19, 2015	May	NEWA

GLUCAGON HYDROCHLORIDE

>A>		POWDER; INTRAMUSCULAR, INTRAVENOUS
>A>		GLUCAGON

>A>	+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N 201849	001	May 08, 2015	May	NEWA
-----	---	--------------------	------------------	----------	-----	--------------	-----	------

GLYCEROL PHENYLBUTYRATELIQUID; ORAL
RAVICTI

>A>	+	HORIZON THERAPS INC	1.1GM/ML	N 203284	001	Feb 01, 2013	May	CAHN
>D>	+	HYPERION THERAP INC	1.1GM/ML	N 203284	001	Feb 01, 2013	May	CAHN

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr	CAHN
AA		2MG	A040844	002	Aug 18, 2009	Apr	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan	CAHN
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr	CAHN
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr	CAHN
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan	CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

>A>	FLOWTUSS						
>A>	MIKART INC	200MG/5ML; 2.5MG/5ML	N022424	001	May 14, 2015	May	NEWA

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	SOLUTION; ORAL						
>A>	HYCOFENIX						
>A>	+ MIKART INC	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	May	NEWA

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

>A>	AB	MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May	NEWA
>A>	AB		EQ 2MG BASE	A202578	002	Jun 02, 2015	May	NEWA
>A>	AB		EQ 3MG BASE	A202578	003	Jun 02, 2015	May	NEWA
>A>	AB		EQ 4MG BASE	A202578	004	Jun 02, 2015	May	NEWA
>A>	AB	SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May	NEWA
>A>	AB		EQ 2MG BASE	A202568	002	Jun 03, 2015	May	NEWA
>A>	AB		EQ 3MG BASE	A202568	003	Jun 03, 2015	May	NEWA
>A>	AB		EQ 4MG BASE	A202568	004	Jun 03, 2015	May	NEWA
>A>	AB	TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May	NEWA
>A>	AB		EQ 2MG BASE	A201382	002	Jun 02, 2015	May	NEWA
>A>	AB		EQ 3MG BASE	A201382	003	Jun 02, 2015	May	NEWA
>A>	AB		EQ 4MG BASE	A201382	004	Jun 02, 2015	May	NEWA
>A>	AB	TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May	NEWA
>A>	AB		EQ 2MG BASE	A201408	002	Jun 02, 2015	May	NEWA
>A>	AB		EQ 3MG BASE	A201408	003	Jun 02, 2015	May	NEWA
>A>	AB		EQ 4MG BASE	A201408	004	Jun 02, 2015	May	NEWA

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>A>	@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May	CAHN
>A>	@		20MG	A071133	001	May 12, 1987	May	CAHN
>D>	@	ROXANE	0.5MG	A071128	001	Feb 17, 1987	May	CAHN
>D>	@		20MG	A071133	001	May 12, 1987	May	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL INTENSOL

>A>	@	CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May	CAHN
>D>	@	ROXANE	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May	CAHN

INJECTABLE; INJECTION

HALOPERIDOL

>D>	@	APOTEX INC	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May	CAHN
	@	CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	CAHN
>A>	@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May	CAHN
AP		MYLAN PHARMS INC	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	Apr	CAHN

HYDROMORPHONE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL						
	HYDROMORPHONE HYDROCHLORIDE						
AB	PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar	NEWA
AB		12MG	A204278	002	Apr 06, 2015	Mar	NEWA
AB		16MG	A204278	003	Apr 06, 2015	Mar	NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION
CYANOKIT

	@ SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr	CAHN
+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION
HYDROXYPROGESTERONE CAPROATE

	@ ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar	CAHN
	@	250MG/ML	N017439	002		Mar	CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

AB	HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
AB		25MG	A204279	002	Aug 20, 2014	Mar	CAHN
AB		50MG	A204279	003	Aug 20, 2014	Mar	CAHN
AB	MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
AB		25MG	A040602	001	Dec 28, 2004	Mar	CMFD
AB		50MG	A040604	001	Dec 28, 2004	Mar	CMFD

HYDROXYZINE PAMOATE

CAPSULE;ORAL
HYDROXYZINE PAMOATE

AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

IFOSFAMIDE

INJECTABLE;INJECTION
IFOSFAMIDE

>A>	AP	MYLAN PHARMS INC	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	May	CAHN
>A>	AP		3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	May	CAHN
>D>	AP	ONCO THERAPIES LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	May	CAHN
>D>	AP		3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	May	CAHN

LLOPERIDONE

TABLET;ORAL
FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan	CAHN
		2MG	N022192	002	May 06, 2009	Jan	CAHN
		4MG	N022192	003	May 06, 2009	Jan	CAHN
		6MG	N022192	004	May 06, 2009	Jan	CAHN
		8MG	N022192	005	May 06, 2009	Jan	CAHN
		10MG	N022192	006	May 06, 2009	Jan	CAHN
		12MG	N022192	007	May 06, 2009	Jan	CAHN

IMIQUIMOD

CREAM;TOPICAL
IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr	CAHN
----	------------------	----	---------	-----	--------------	-----	------

INGENOL MEBUTATE

GEL;TOPICAL
PICATO

>D>		LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May	CRLD
>A>	+		0.015%	N202833	001	Jan 23, 2012	May	CRLD

INSULIN GLARGINE

SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR

+	SANOFI US SERVICES	300UNITS/ML (300UNITS/ML)	N206538	001	Feb 25, 2015	Feb	NEWA
---	--------------------	---------------------------	---------	-----	--------------	-----	------

INSULIN GLARGINE RECOMBINANTSOLUTION; SUBCUTANEOUS
TOUJEO SOLOSTAR

+ SANOFI US SERVICES 300UNITS/ML (300UNITS/ML) N206538 001 Feb 25, 2015 Feb NEWA

INSULIN LISPRO RECOMBINANTSOLUTION; SUBCUTANEOUS
HUMALOG KWIKPEN>A>
>A> + ELI LILLY AND CO 200 UNITS/ML N205747 001 May 26, 2015 May NEWAINSULIN RECOMBINANT HUMANPOWDER; INHALATION
AFREZZA

SANOFI AVENTIS 12 UNITS/INH N022472 003 Apr 17, 2015 Apr NEWA

IOHEXOLFOR SOLUTION; ORAL
ORALTAG

INTERPHARMA PRAHA AS 9.7GM/BOT N205383 001 Mar 26, 2015 Mar NEWA

IOPAMIDOLINJECTABLE; INJECTION
IOPAMIDOL-250@ FRESENIUS KABI USA 51% A074679 001 Apr 02, 1997 Jan DISC
IOPAMIDOL-300@ FRESENIUS KABI USA 61% A074679 002 Apr 02, 1997 Jan DISC
IOPAMIDOL-370@ FRESENIUS KABI USA 76% A074679 003 Apr 02, 1997 Jan DISC
ISOVUE-200+ BRACCO 41% N018735 006 Jul 07, 1987 Feb CTEC
ISOVUE-250

+ BRACCO 51% N018735 007 Jul 06, 1992 Feb CTEC

+ 51% N020327 002 Oct 12, 1994 Feb CTEC

ISOVUE-300

+ BRACCO 61% N020327 003 Oct 12, 1994 Feb CTEC

ISOVUE-370

+ BRACCO 76% N020327 004 Oct 12, 1994 Feb CTEC

IOTHALAMATE MEGLUMINEINJECTABLE; INJECTION
CONRAY

+ LIEBEL-FLARSHEIM 60% N013295 001 Feb CAHN

CONRAY 30

+ LIEBEL-FLARSHEIM 30% N016983 001 Feb CAHN

CONRAY 43

+ LIEBEL-FLARSHEIM 43% N013295 002 Feb CAHN

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

LIEBEL-FLARSHEIM 17.2% N017057 002 Feb CAHN

IOVERSOLINJECTABLE; INJECTION
OPTIRAY 160

@ LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988 Feb CAHN

OPTIRAY 240

+ LIEBEL-FLARSHEIM 51% N019710 002 Dec 30, 1988 Feb CAHN

@ 51% N020923 001 May 28, 1998 Feb CAHN

OPTIRAY 300

+ LIEBEL-FLARSHEIM 64% N019710 004 Jan 22, 1992 Feb CAHN

+ 64% N020923 004 May 13, 1999 Feb CAHN

OPTIRAY 320

+ LIEBEL-FLARSHEIM 68% N019710 001 Dec 30, 1988 Feb CAHN

@ 68% N020923 002 May 29, 1998 Feb CAHN

OPTIRAY 350

+ LIEBEL-FLARSHEIM 74% N019710 005 Jan 22, 1992 Feb CAHN

+ 74% N020923 003 May 28, 1998 Feb CAHN

>D>	<u>IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM</u>						
>D>	INJECTABLE; INJECTION						
>D>	HEXABRIX						
>D>	+	GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985	May DISC
>A>		@	39.3%;19.6%	N018905	002	Jul 26, 1985	May DISC
	<u>IRBESARTAN</u>						
	TABLET; ORAL						
	IRBESARTAN						
AB		JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb NEWA
AB			150MG	A203534	002	Feb 23, 2015	Feb NEWA
AB			300MG	A203534	003	Feb 23, 2015	Feb NEWA
	<u>IRON DEXTRAN</u>						
	INJECTABLE; INJECTION						
	INFED						
BP	+	ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001		Mar CAHN
	<u>ISAVUCONAZONIUM SULFATE</u>						
	CAPSULE; ORAL						
	CRESEMBA						
	+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar NEWA
	POWDER; IV (INFUSION)						
	CRESEMBA						
	+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar NEWA
	<u>ISOSORBIDE DINITRATE</u>						
	TABLET; ORAL						
	ISORDIL						
AB		VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb CAHN
		@	10MG	N012093	002	Jul 29, 1988	Feb CAHN
		@	20MG	N012093	006	Jul 29, 1988	Feb CAHN
		@	30MG	N012093	005	Jul 29, 1988	Feb CAHN
	+		40MG	N012093	001	Jul 29, 1988	Feb CAHN
	<u>ISOTRETINOIN</u>						
	CAPSULE; ORAL						
	ABSORICA						
		RANBAXY	25MG	N021951	005	Aug 15, 2014	Feb NEWA
			35MG	N021951	006	Aug 15, 2014	Feb NEWA
	SOTRET						
AB		SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr CAHN
AB			20MG	A076041	002	Dec 24, 2002	Apr CAHN
AB			30MG	A076503	001	Jun 20, 2003	Apr CAHN
AB			40MG	A076041	003	Dec 24, 2002	Apr CAHN
	ZENATANE						
AB		DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb NEWA
	<u>ISRADIPINE</u>						
	CAPSULE; ORAL						
	ISRADIPINE						
AB		ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar CAHN
AB			5MG	A077169	002	Apr 24, 2006	Mar CAHN
	<u>IVABRADINE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	CORLANOR						
		AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr NEWA
	+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr NEWA
	<u>IVACAFTOR</u>						
	GRANULE; ORAL						
	KALYDECO						
		VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar NEWA
	+		75MG/PACKET	N207925	002	Mar 17, 2015	Mar NEWA

KETOROLAC TROMETHAMINE

	INJECTABLE; INJECTION							
	KETOROLAC TROMETHAMINE							
	@ CLARIS PHARMASERVICE	15MG/ML	A 075631	002	Jun 29, 2001	Apr	CAHN	
	@	30MG/ML	A 075631	001	Jun 29, 2001	Apr	CAHN	
AP	MYLAN PHARMS INC	15MG/ML	A 078299	001	Jul 16, 2007	Apr	CAHN	
AP		30MG/ML	A 078299	002	Jul 16, 2007	Apr	CAHN	
	SPRAY, METERED; NASAL							
	SPRIX							
	+ EGALET US INC	15.75MG/SPRAY	N 022382	001	May 14, 2010	Jan	CAHN	

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION; IRRIGATION							
	OMIDRIA							
	+ OMEROS	EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N 205388	001	May 30, 2014	Feb	CPOT	

LABETALOL HYDROCHLORIDE

	INJECTABLE; INJECTION							
	LABETALOL HYDROCHLORIDE							
	@ CLARIS PHARMASERVICE	5MG/ML	A 076051	001	Jul 05, 2002	Apr	CAHN	
	TABLET; ORAL							
	LABETALOL HYDROCHLORIDE							
AB	MUTUAL PHARM	100MG	A 075215	001	Jul 29, 1999	Jan	CMFD	
AB		200MG	A 075215	002	Jul 29, 1999	Jan	CMFD	
AB		300MG	A 075215	003	Jul 29, 1999	Jan	CMFD	

LACTULOSE

	SOLUTION; ORAL, RECTAL							
	LACTULOSE							
AA	BIO-PHARM INC	10GM/15ML	A 203762	001	Mar 27, 2015	Mar	NEWA	

LAMIVUDINE; RALTEGRAVIR POTASSIUM

	TABLET; ORAL							
	DUTREBIS							
	+ MERCK SHARP DOHME	150MG; EQ 300MG BASE	N 206510	001	Feb 06, 2015	Feb	NEWA	

LAMIVUDINE; ZIDOVUDINE

	TABLET; ORAL							
	LAMIVUDINE AND ZIDOVUDINE							
AB	STRIDES ARCOLAB LTD	150MG; 300MG	A 079128	001	May 13, 2015	Apr	NEWA	

LAMOTRIGINE

	TABLET; ORAL							
	LAMOTRIGINE							
>D> AB	HIKMA PHARMS	25MG	A 078134	001	Apr 19, 2011	May	DISC	
>A>	@	25MG	A 078134	001	Apr 19, 2011	May	DISC	
>D> AB		100MG	A 078134	002	Apr 19, 2011	May	DISC	
>A>	@	100MG	A 078134	002	Apr 19, 2011	May	DISC	
>D> AB		150MG	A 078134	003	Apr 19, 2011	May	DISC	
>A>	@	150MG	A 078134	003	Apr 19, 2011	May	DISC	
>D> AB		200MG	A 078134	004	Apr 19, 2011	May	DISC	
>A>	@	200MG	A 078134	004	Apr 19, 2011	May	DISC	

LAPATINIB DITOSYLATE

	TABLET; ORAL							
	TYKERB							
	+ NOVARTIS PHARMS CORP	EQ 250MG BASE	N 022059	001	Mar 13, 2007	Mar	CAHN	

LENVATINIB MESYLATE

	CAPSULE; ORAL							
	LENVIMA							
	EISAI INC	EQ 4MG BASE	N 206947	001	Feb 13, 2015	Feb	NEWA	
	+	EQ 10MG BASE	N 206947	002	Feb 13, 2015	Feb	NEWA	

LEVETIRACETAM

	SOLUTION; ORAL							
	LEVETIRACETAM							
>A> AA	PHARM ASSOC	100MG/ML	A 201157	001	Jun 04, 2015	May	NEWA	

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

	SPARC	1GM	N204417	001	Mar 02, 2015	Mar	NEWA
		1.5GM	N204417	002	Mar 02, 2015	Mar	NEWA
	LEVETIRACETAM						
	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb	NEWA
>A>	PRINSTON INC	500MG	A203468	001	May 21, 2015	May	NEWA
>A>		750MG	A203468	002	May 21, 2015	May	NEWA

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

	@ TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr	DISC
--	-------------------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb	NEWA
----	------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	CAHN
		LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr	CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr	CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr	CAHN

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

	SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb	NEWA
	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb	NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar	CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb	NEWA
--	--------------	------	---------	-----	--------------	-----	------

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr	CAHN
---	---------------------	-----	---------	-----	--------------	-----	------

LIDOCAINE

PATCH;TOPICAL

LIDOCAINE

AB	ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar	CAHN
----	---------------------	----	---------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>D>	AP	AGILA SPECLTS	0.5%	A091056	001	Dec 08, 2010	May	CAHN
>D>	AP		0.5%	A091058	001	Sep 30, 2010	May	CAHN
>D>	AP		1%	A091056	002	Dec 08, 2010	May	CAHN
>D>	AP		1%	A091058	002	Sep 30, 2010	May	CAHN
	@	EUROHLTH INTL SARL	1%	A080407	001		Mar	CAHN
	@		2%	A080407	002		Mar	CAHN
>A>	AP	MYLAN PHARMS INC	0.5%	A091056	001	Dec 08, 2010	May	CAHN
>A>	AP		0.5%	A091058	001	Sep 30, 2010	May	CAHN
>A>	AP		1%	A091056	002	Dec 08, 2010	May	CAHN
>A>	AP		1%	A091058	002	Sep 30, 2010	May	CAHN
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
>D>	AP	AGILA SPECLTS	2%	A090665	001	Sep 27, 2010	May	CAHN
	@	EUROHLTH INTL SARL	1%	A084625	001		Feb	CAHN
	@		2%	A084625	002		Feb	CAHN
>A>	AP	MYLAN PHARMS INC	2%	A090665	001	Sep 27, 2010	May	CAHN

JELLY; TOPICAL

ANESTACON

@ BANNER LIFE SCIENCES 2%

A080429 001

Jan CAHN

LIDOCAINE HYDROCHLORIDE

@ G AND W LABS INC 2%

A081318 001 Apr 29, 1993

Apr CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB + ACTAVIS LABS UT INC 2.5%;2.5%

N019941 001 Dec 30, 1992

Feb CAHN

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS LLC 145MCG

N202811 001 Aug 30, 2012

Mar CAHN

+ 290MCG

N202811 002 Aug 30, 2012

Mar CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

>D> + PHARMACIA AND UPJOHN EQ 300MG BASE/ML

N050317 001

May CFTG

>A> AP + EQ 300MG BASE/ML

N050317 001

May CFTG

>A> LINCOMYCIN

>A> AP X-GEN PHARMS INC EQ 300MG BASE/ML

A201746 001 Jun 04, 2015

May NEWA

LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID

>A> AB ROXANE 100MG/5ML

A200068 001 Jun 03, 2015

May NEWA

ZYVOX

>D> + PHARMACIA AND UPJOHN 100MG/5ML

N021132 001

Apr 18, 2000 May CFTG

>A> AB + 100MG/5ML

N021132 001

Apr 18, 2000 May CFTG

>D> INJECTABLE; INJECTION

>D> LINEZOLID

>D> AP TEVA PHARMS 200MG/100ML

A200222 001 Jun 27, 2012

May CDFR

>D> ZYVOX

>D> AP + PHARMACIA AND UPJOHN 200MG/100ML

N021131 001

Apr 18, 2000 May CDFR

>A> SOLUTION; IV (INFUSION)

>A> LINEZOLID

>A> AP TEVA PHARMS 600MG/300ML (2MG/ML)

A200222 001 Jun 27, 2012

May CDFR

>A> ZYVOX

>A> PHARMACIA AND UPJOHN 200MG/100ML (2MG/ML)

N021131 001

Apr 18, 2000 May CDFR

>A> 400MG/200ML (2MG/ML)

N021131 002

Apr 18, 2000 May NEWA

>A> AP + 600MG/300ML (2MG/ML)

N021131 003

Apr 18, 2000 May NEWA

TABLET; ORAL

LINEZOLID

>A> AB TEVA PHARMS USA 600MG

A078061 001

May 18, 2015 May NEWA

ZYVOX

>D> + PHARMACIA AND UPJOHN 600MG

N021130 002

Apr 18, 2000 May CFTG

>A> AB + 600MG

N021130 002

Apr 18, 2000 May CFTG

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB SUN PHARM INDS LTD 2.5MG

A075944 001 Jul 01, 2002

Apr CAHN

AB 5MG

A075944 002

Jul 01, 2002 Apr CAHN

AB 10MG

A075944 003

Jul 01, 2002 Apr CAHN

AB 20MG

A075944 004

Jul 01, 2002 Apr CAHN

AB 30MG

A075944 006

Feb 11, 2003 Apr CAHN

AB 40MG

A075944 005

Jul 01, 2002 Apr CAHN

ZESTRIL

AB ALVOGEN IPCO SARL 2.5MG

N019777 005

Apr 29, 1993 Feb CAHN

AB 5MG

N019777 001

May 19, 1988 Feb CAHN

AB 10MG

N019777 002

May 19, 1988 Feb CAHN

AB 20MG

N019777 003

May 19, 1988 Feb CAHN

AB 30MG

N019777 006

Jan 20, 1999 Feb CAHN

AB + 40MG

N019777 004

May 19, 1988 Feb CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

>A>	AB	ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May NEWA
		@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb DISC

LOMITAPIDE MESYLATE

CAPSULE;ORAL
JUXTAPID

		AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr NEWA
			EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr NEWA
			EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr NEWA

LOMUSTINE

CAPSULE;ORAL
GLEOSTINE

		CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jan NEWA
--	--	---------------	-----	---------	-----	--------------	----------

LORAZEPAM

TABLET;ORAL
LORAZEPAM

AB		SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Apr CAHN
AB			1MG	A076045	002	Aug 29, 2001	Apr CAHN
AB			2MG	A076045	003	Aug 29, 2001	Apr CAHN

LOSARTAN POTASSIUM

TABLET;ORAL
LOSARTAN POTASSIUM

AB		WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb CMFD
AB			50MG	A091129	002	Oct 06, 2010	Feb CMFD
AB			100MG	A091129	003	Oct 06, 2010	Feb CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL
ALTOPREV

>D>		@ ANDRX LABS LLC	10MG	N021316	001	Jun 26, 2002	May CAHN
>D>			20MG	N021316	002	Jun 26, 2002	May CAHN
>D>			40MG	N021316	003	Jun 26, 2002	May CAHN
>D>		+	60MG	N021316	004	Jun 26, 2002	May CAHN
>A>		@ COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	May CAHN
>A>			20MG	N021316	002	Jun 26, 2002	May CAHN
>A>			40MG	N021316	003	Jun 26, 2002	May CAHN
>A>		+	60MG	N021316	004	Jun 26, 2002	May CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL
LOXITANE C

		@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar CAHN
--	--	-----------------------	-----------------	---------	-----	--	----------

INJECTABLE;INJECTION
LOXITANE IM

		@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar CAHN
--	--	-----------------------	-----------------	---------	-----	--	----------

LOXAPINE SUCCINATE

CAPSULE;ORAL
LOXAPINE SUCCINATE

>A>	AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CAHN
>A>	AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CAHN
>A>	AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CAHN
>A>	AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CAHN
>D>	AB	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CAHN
>D>	AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CAHN
>D>	AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CAHN
>D>	AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CAHN

LOXITANE

		@ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar CAHN
		@	EQ 10MG BASE	N017525	002		Mar CAHN
		@	EQ 25MG BASE	N017525	003		Mar CAHN
		@	EQ 50MG BASE	N017525	004		Mar CAHN

TABLET;ORAL
LOXITANE

		@ ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar CAHN
--	--	-----------------------	--------------	---------	-----	--	----------

TABLET;ORAL
LOXITANE

@	EQ 25MG BASE	N017525	007			Mar	CAHN
@	EQ 50MG BASE	N017525	008			Mar	CAHN

>D> LUCINACTANT

>D> SUSPENSION;INTRATRACHEAL
>D> SURFAXIN

>D>	+	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May	DISC
>A>	@		8.5ML	N021746	001	Mar 06, 2012	May	DISC

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION
PLASMA-LYTE 56 IN PLASTIC CONTAINER
@ BAXTER HLTHCARE

32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC
------------------------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP		EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr	CDFR
AP	+	FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr	CPOT
AP	+	HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr	CDFR
		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr	NEWA

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr	NEWA
---	--------------------	--------------------	---------	-----	--------------	-----	------

MANNITOL

INJECTABLE;INJECTION
MANNITOL 25%

@	IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar	CAHN
@		12.5GM/50ML	A089240	001	May 06, 1987	Mar	CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR

		FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar	CAHN
			14MG	N022525	002	Jun 21, 2010	Mar	CAHN
			21MG	N022525	003	Jun 21, 2010	Mar	CAHN
	+		28MG	N022525	004	Jun 21, 2010	Mar	CAHN

SOLUTION;ORAL

+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar	CAHN
---	-----------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL
MEMANTINE

AB		SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar	CMFD
AB			10MG	A090058	002	May 05, 2010	Mar	CMFD
		MEMANTINE HYDROCHLORIDE						
AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar	NEWA
AB			10MG	A090041	002	Apr 10, 2015	Mar	NEWA
AB		LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar	NEWA
AB			10MG	A090051	002	Apr 10, 2015	Mar	NEWA
	@	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Mar	DISC
AB			5MG	A079225	001	Jan 30, 2015	Jan	NEWA
	@		10MG	A079225	002	Jan 30, 2015	Mar	DISC
AB			10MG	A079225	002	Jan 30, 2015	Jan	NEWA
>D>	@	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May	CMFD
>A>	AB		5MG	A090052	001	Oct 25, 2011	May	CMFD
>D>	@		10MG	A090052	002	Oct 25, 2011	May	CMFD
>A>	AB		10MG	A090052	002	Oct 25, 2011	May	CMFD
		NAMENDA						
AB		FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar	CAHN
AB	+		10MG	N021487	002	Oct 16, 2003	Mar	CAHN

MENOTROPINS (FSH; LH)

>D> INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
>D> REPRONEX

>D>	+	FERRING	75 IU/VIAL	N021047	001	Aug 27, 1999	May	DISC
>A>	@		75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May	DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE

>D>	@	ASTRAZENECA	25MG/ML	A 089781	001	Mar 31, 1989	May	CAHN
AP		EUROHLTH INTL SARL	25MG/ML	A 080445	001		Feb	CAHN
AP			50MG/ML	A 080445	002		Feb	CAHN
AP			75MG/ML	A 080445	003		Feb	CAHN
AP			100MG/ML	A 080445	004		Feb	CAHN
>A>	@	IGI LABS INC	25MG/ML	A 089781	001	Mar 31, 1989	May	CAHN
	@		50MG/ML	A 089782	001	Mar 31, 1989	Mar	CAHN
	@		50MG/ML	A 089783	001	Mar 31, 1989	Mar	CAHN
	@		50MG/ML	A 089784	001	Mar 31, 1989	Mar	CAHN
	@		75MG/ML	A 089785	001	Mar 31, 1989	Mar	CAHN
	@		100MG/ML	A 089786	001	Mar 31, 1989	Mar	CAHN
	@		100MG/ML	A 089787	001	Mar 31, 1989	Mar	CAHN
	@		100MG/ML	A 089788	001	Mar 31, 1989	Mar	CAHN

MEROPENEM

POWDER; IV (INFUSION)
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

		B BRAUN MEDICAL INC	1GM/VIAL	N202106	002	Apr 30, 2015	Apr	NEWA
			500MG/VIAL	N202106	001	Apr 30, 2015	Apr	NEWA

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20
NORINYL

	@	ACTAVIS LABS UT INC	0.1MG; 2MG	N 013625	004		Mar	CAHN
--	---	---------------------	------------	----------	-----	--	-----	------

TABLET; ORAL-21

NORINYL 1+50 21-DAY

	@	ACTAVIS LABS UT INC	0.05MG; 1MG	N 013625	002		Mar	CAHN
--	---	---------------------	-------------	----------	-----	--	-----	------

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+		ACTAVIS LABS UT INC	0.05MG; 1MG	N 016659	001		Mar	CAHN
---	--	---------------------	-------------	----------	-----	--	-----	------

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE

	@	MYLAN SPECLT	0.4%	A 071786	001	Aug 05, 1988	Apr	DISC
	@		0.6%	A 070804	001	Aug 17, 1987	Apr	DISC
	@	WOCKHARDT	0.4%	A 075586	001	May 30, 2002	Apr	DISC
	@		0.6%	A 075586	002	May 30, 2002	Apr	DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

	@	G AND W LABS INC	10MG/5ML	A 072761	001	Feb 27, 1992	Apr	CAHN
	@		10MG/5ML	A 073034	001	Aug 30, 1991	Apr	CAHN

METAXALONE

TABLET; ORAL

METAXALONE

		COREPHARMA	400MG	A 040486	001	Feb 27, 2015	Feb	NEWA
--	--	------------	-------	----------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+		SUN PHARM INDS LTD	500MG/5ML	N 021591	001	Sep 11, 2003	Apr	CAHN
---	--	--------------------	-----------	----------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

>D>		SB PHARMCO	1GM; EQ 2MG BASE	N 021410	004	Aug 25, 2003	May	DISC
>A>	@		1GM; EQ 2MG BASE	N 021410	004	Aug 25, 2003	May	DISC
>D>	AB	+	1GM; EQ 4MG BASE	N 021410	005	Aug 25, 2003	May	DISC
>A>	@		1GM; EQ 4MG BASE	N 021410	005	Aug 25, 2003	May	DISC
>D>	AB		500MG; EQ 2MG BASE	N 021410	002	Oct 10, 2002	May	DISC
>A>	@		500MG; EQ 2MG BASE	N 021410	002	Oct 10, 2002	May	DISC
>D>	AB		500MG; EQ 4MG BASE	N 021410	003	Oct 10, 2002	May	DISC
>A>	@		500MG; EQ 4MG BASE	N 021410	003	Oct 10, 2002	May	DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

>D>	AB		TEVA	1GM; EQ 4MG BASE	A 077337	004	May 07, 2014	May	CRLD
>A>	+			1GM; EQ 4MG BASE	A 077337	004	May 07, 2014	May	CRLD
>D>	AB			1GM; EQ 2MG BASE	A 077337	003	May 07, 2014	May	CTEC

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

>A>		1GM;EQ 2MG BASE	A 077337	003	May 07, 2014	May CTEC
>D>	AB	500MG;EQ 2MG BASE	A 077337	001	May 07, 2014	May CTEC
>A>		500MG;EQ 2MG BASE	A 077337	001	May 07, 2014	May CTEC
>D>	AB	500MG;EQ 4MG BASE	A 077337	002	May 07, 2014	May CTEC
>A>		500MG;EQ 4MG BASE	A 077337	002	May 07, 2014	May CTEC

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB	HERITAGE PHARMA	5MG	A 040734	001	Dec 14, 2007	Mar CAHN
AB		10MG	A 040734	002	Dec 14, 2007	Mar CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE PRESERVATIVE FREE

>D>	@ FRESENIUS KABI USA	EQ 25MG BASE/ML	A 040265	001	Feb 26, 1999	May CMFD	
>A>	AP	EQ 25MG BASE/ML	A 040265	001	Feb 26, 1999	May CMFD	
		METHOTREXATE SODIUM PRESERVATIVE FREE					
>A>	AP	MYLAN LABS INC	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	May CAHN
>D>	AP	ONCO THERAPIES LTD	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	May CAHN

TABLET;ORAL

METHOTREXATE SODIUM

>A>	AB	ORION CORP ORION	EQ 2.5MG BASE	A 201749	001	May 21, 2015	May NEWA
-----	----	------------------	---------------	----------	-----	--------------	----------

METHOXSALEN

CAPSULE;ORAL

METHOXSALEN

>A>	AB	ACTAVIS INC	10MG	A 202603	001	Jun 09, 2015	May NEWA
-----	----	-------------	------	----------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

APTENSIO XR

RHODES PHARMS

		10MG	N 205831	001	Apr 17, 2015	Apr NEWA
		15MG	N 205831	002	Apr 17, 2015	Apr NEWA
		20MG	N 205831	003	Apr 17, 2015	Apr NEWA
		30MG	N 205831	004	Apr 17, 2015	Apr NEWA
		40MG	N 205831	005	Apr 17, 2015	Apr NEWA
		50MG	N 205831	006	Apr 17, 2015	Apr NEWA
	+	60MG	N 205831	007	Apr 17, 2015	Apr NEWA
		RITALIN LA				
AB1	NOVARTIS	40MG	N 021284	003	Jun 05, 2002	Feb CRLD
	+	60MG	N 021284	005	Oct 27, 2014	Feb CRLD

TABLET, CHEWABLE;ORAL

METHYLIN

AB	MALLINCKRODT	2.5MG	N 021475	001	Apr 15, 2003	Feb CFTG
AB		5MG	N 021475	002	Apr 15, 2003	Feb CFTG
AB	+	10MG	N 021475	003	Apr 15, 2003	Feb CFTG

METHYLPHENIDATE HYDROCHLORIDE

AB	NOVEL LABS INC	2.5MG	A 204115	001	Feb 25, 2015	Feb NEWA
AB		5MG	A 204115	002	Feb 25, 2015	Feb NEWA
AB		10MG	A 204115	003	Feb 25, 2015	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

METHYLIN ER

>D>	MALLINCKRODT INC	10MG	A 075629	001	May 09, 2000	May CTEC	
>A>	AB	10MG	A 075629	001	May 09, 2000	May CTEC	
		METHYLPHENIDATE HYDROCHLORIDE					
>A>	AB	ABHAI	10MG	A 207488	001	Jun 09, 2015	May NEWA
>A>	AB	20MG	A 207488	002	Jun 09, 2015	May NEWA	

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP	CLARIS PHARMASERVICE	1MG/ML	A 078950	001	Apr 29, 2013	Apr CAHN
----	----------------------	--------	----------	-----	--------------	----------

TABLET;ORAL

METOPROLOL TARTRATE

	MYLAN	37.5MG	A 076704	004	Mar 18, 2015	Mar NEWA
		75MG	A 076704	005	Mar 18, 2015	Mar NEWA

METRONIDAZOLE

	CREAM; TOPICAL								
	NORITATE								
	+ VALEANT PHARMS NORTH	1%		N020743	001	Sep 26, 1997	Feb	CAHN	
	GEL; VAGINAL								
	METRONIDAZOLE								
	+ ACTAVIS LABS UT INC	1.3%		N205223	001	Mar 24, 2014	Feb	CAHN	
	NUVESSA								
	+ ACTAVIS LABS UT INC	1.3%		N205223	001	Mar 24, 2014	Feb	CTNA	
	INJECTABLE; INJECTION								
	METRONIDAZOLE IN PLASTIC CONTAINER								
AP	CLARIS PHARMASERVICE	500MG/100ML		A078084	001	Mar 31, 2008	Apr	CAHN	
	TABLET; ORAL								
	METRONIDAZOLE								
>A>	AB AUROBINDO PHARMA LTD	250MG		A203974	001	May 29, 2015	May	NEWA	
>A>	AB	500MG		A203974	002	May 29, 2015	May	NEWA	

MICONAZOLE

	TABLET; BUCCAL								
	ORAVIG								
	+ DARA BIOSCIENCES	50MG		N022404	001	Apr 16, 2010	Apr	CAHN	

MIDAZOLAM HYDROCHLORIDE

	INJECTABLE; INJECTION								
	MIDAZOLAM HYDROCHLORIDE								
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML		A075637	001	Oct 31, 2000	Apr	CAHN	
	@	EQ 5MG BASE/ML		A075637	002	Oct 31, 2000	Apr	CAHN	
	@ IGI LABS INC	EQ 5MG BASE/ML		A075263	001	Jun 26, 2000	Apr	CAHN	
	@ WOCKHARDT	EQ 1MG BASE/ML		A078141	001	May 30, 2008	Mar	DISC	
	@	EQ 1MG BASE/ML		A078511	001	Nov 10, 2008	Mar	DISC	
	@	EQ 5MG BASE/ML		A078141	002	May 30, 2008	Mar	DISC	
	@	EQ 5MG BASE/ML		A078511	002	Nov 10, 2008	Mar	DISC	
	SYRUP; ORAL								
	MIDAZOLAM HYDROCHLORIDE								
AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML		A076058	001	Mar 15, 2002	Apr	CAHN	

MIGLITOL

	TABLET; ORAL								
	GLYSET								
AB	PHARMACIA AND UPJOHN	25MG		N020682	001	Dec 18, 1996	Mar	CTEC	
AA		25MG		N020682	001	Dec 18, 1996	Feb	CFTG	
AB		50MG		N020682	002	Dec 18, 1996	Mar	CTEC	
AA		50MG		N020682	002	Dec 18, 1996	Feb	CFTG	
AB	+	100MG		N020682	003	Dec 18, 1996	Mar	CTEC	
AA	+	100MG		N020682	003	Dec 18, 1996	Feb	CFTG	
	MIGLITOL								
AB	ORIENT PHARMA CO LTD	25MG		A203965	001	Feb 24, 2015	Mar	CTEC	
AA		25MG		A203965	001	Feb 24, 2015	Feb	NEWA	
AB		50MG		A203965	002	Feb 24, 2015	Mar	CTEC	
AA		50MG		A203965	002	Feb 24, 2015	Feb	NEWA	
AB		100MG		A203965	003	Feb 24, 2015	Mar	CTEC	
AA		100MG		A203965	003	Feb 24, 2015	Feb	NEWA	

MILRINONE LACTATE

	INJECTABLE; INJECTION								
	MILRINONE LACTATE								
AP	BEDFORD	EQ 1MG BASE/ML		A075660	001	May 28, 2002	Jan	CRLD	
AP	+ HIKMA FARMACEUTICA	EQ 1MG BASE/ML		A077966	001	Dec 03, 2010	Jan	CRLD	

MINOCYCLINE HYDROCHLORIDE

	CAPSULE; ORAL								
	MINOCYCLINE HYDROCHLORIDE								
AB	SUN PHARM INDS LTD	EQ 50MG BASE		A065062	001	Nov 30, 2000	Apr	CAHN	
AB		EQ 75MG BASE		A065062	002	Nov 30, 2000	Apr	CAHN	
AB		EQ 100MG BASE		A065062	003	Nov 30, 2000	Apr	CAHN	
	CAPSULE, EXTENDED RELEASE; ORAL								
	XIMINO								
	@ SUN PHARM INDS LTD	EQ 45MG BASE		N201922	001	Jul 11, 2012	Apr	CAHN	
	@	EQ 67.5MG BASE		N201922	002	Jul 11, 2012	Apr	CAHN	
	@	EQ 90MG BASE		N201922	003	Jul 11, 2012	Apr	CAHN	
	@	EQ 112.5MG BASE		N201922	004	Jul 11, 2012	Apr	CAHN	

CAPSULE, EXTENDED RELEASE;ORAL							
XIMINO							
	@	EQ 135MG BASE		N201922	005	Jul 11, 2012	Apr CAHN
TABLET;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 50MG BASE		A065156	001	Jan 06, 2004	Apr CAHN
AB		EQ 75MG BASE		A065156	002	Jan 06, 2004	Apr CAHN
AB		EQ 100MG BASE		A065156	003	Jan 06, 2004	Apr CAHN
TABLET, EXTENDED RELEASE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 45MG BASE		A091118	001	Sep 25, 2014	Apr CAHN
AB		EQ 80MG BASE		A091118	004	Sep 25, 2014	Apr CAHN
AB		EQ 90MG BASE		A091118	005	Sep 25, 2014	Apr CAHN
AB		EQ 105MG BASE		A091118	006	Sep 25, 2014	Apr CAHN
AB		EQ 135MG BASE		A091118	008	Sep 25, 2014	Apr CAHN
<u>MIVACURIUM CHLORIDE</u>							
INJECTABLE;INJECTION							
MIVACURIUM CHLORIDE							
>D>	@	AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	May CAHN
>A>	@	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	May CAHN
SOLUTION;INTRAVENOUS							
MIVACRON							
	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)		N020098	004	Jan 22, 1992	Jan NEWA
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)		N020098	005	Jan 22, 1992	Jan NEWA
<u>MOLINDONE HYDROCHLORIDE</u>							
TABLET;ORAL							
MOLINDONE HYDROCHLORIDE							
	COREPHARMA	5MG		A090453	001	Mar 20, 2015	Mar NEWA
		10MG		A090453	002	Mar 20, 2015	Mar NEWA
+		25MG		A090453	003	Mar 20, 2015	Mar NEWA
<u>MONTELUKAST SODIUM</u>							
TABLET;ORAL							
MONTELUKAST SODIUM							
AB	KREMERS URBAN PHARMS	EQ 10MG BASE		A201522	001	Aug 03, 2012	Mar CAHN
TABLET, CHEWABLE;ORAL							
MONTELUKAST SODIUM							
>A>	AB	HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
>A>	AB		EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
	AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
	AB		EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
	AB	KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
	AB		EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
	AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
	AB		EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA
<u>MORPHINE SULFATE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
KADIAN							
AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
	AB1		20MG	N020616	001	Jul 03, 1996	Mar CAHN
	AB1		30MG	N020616	004	Mar 09, 2001	Mar CAHN
>D>			40MG	N020616	009	Jul 09, 2012	May CTEC
>A>	AB1		40MG	N020616	009	Jul 09, 2012	May CTEC
			40MG	N020616	009	Jul 09, 2012	Mar CAHN
	AB1		50MG	N020616	002	Jul 03, 1996	Mar CAHN
	AB1		60MG	N020616	005	Mar 09, 2001	Mar CAHN
>D>			70MG	N020616	010	Jul 09, 2012	May CTEC
>A>	AB1		70MG	N020616	010	Jul 09, 2012	May CTEC
			70MG	N020616	010	Jul 09, 2012	Mar CAHN
	AB1		80MG	N020616	006	Oct 27, 2006	Mar CAHN
	AB1	+	100MG	N020616	003	Jul 03, 1996	Mar CAHN
			130MG	N020616	011	Jul 09, 2012	Mar CAHN
			150MG	N020616	012	Jul 09, 2012	Mar CAHN
	AB1	+	200MG	N020616	007	Feb 27, 2007	Mar CAHN
MORPHINE SULFATE							
>A>	AB1	TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May NEWA
>A>	AB1		70MG	A202718	008	Jun 03, 2015	May NEWA

INJECTABLE; INJECTION
MORPHINE SULFATE

>A>	AP	EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May	NEWA
>A>	AP		8MG/ML	A205758	002	May 21, 2015	May	NEWA
>A>	AP		10MG/ML	A205758	003	May 21, 2015	May	NEWA
>D>	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May	CFTG
>A>	AP		4MG/ML	N202515	002	Nov 14, 2011	May	CFTG
>D>	+		8MG/ML	N202515	003	Nov 14, 2011	May	CFTG
>A>	AP		8MG/ML	N202515	003	Nov 14, 2011	May	CFTG
>D>	+		10MG/ML	N202515	004	Nov 14, 2011	May	CFTG
>A>	AP		10MG/ML	N202515	004	Nov 14, 2011	May	CFTG

SOLUTION; ORAL
MORPHINE SULFATE

>A>	AA	TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May	NEWA
>A>	AA		100MG/5ML	A203518	002	May 12, 2015	May	NEWA

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar	NEWA
AB			30MG	A203849	002	Apr 06, 2015	Mar	NEWA
AB			60MG	A203849	003	Apr 06, 2015	Mar	NEWA
AB			100MG	A203849	004	Apr 06, 2015	Mar	NEWA
AB			200MG	A203849	005	Apr 06, 2015	Mar	NEWA
AB		SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr	CAHN
AB			30MG	A078761	002	May 11, 2012	Apr	CAHN
AB			60MG	A078761	003	May 11, 2012	Apr	CAHN
AB			100MG	A078761	004	May 11, 2012	Apr	CAHN
AB			200MG	A078761	005	May 11, 2012	Apr	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION; IV (INFUSION)
MOXIFLOXACIN HYDROCHLORIDE

+		FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr	NEWA
---	--	--------------------	--	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC
MOXEZA

>D>	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CFTG
>A>	AT2		EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CFTG
>D>	AT	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May	CTEC
>A>	AT1		EQ 0.5% BASE	A202867	001	Sep 04, 2014	May	CTEC
>A>	AT2		EQ 0.5% BASE	A204079	001	May 28, 2015	May	NEWA
>D>	AT	WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May	CTEC
>A>	AT1		EQ 0.5% BASE	A202525	001	Mar 06, 2015	May	CTEC
			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb	NEWA
		VIGAMOX						
>D>	AT	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May	CTEC
>A>	AT1		EQ 0.5% BASE	N021598	001	Apr 15, 2003	May	CTEC

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HYDROCHLORIDE

@		IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
@			10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
@			10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
@			20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
@			20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
@			20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE

@		EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar	CAHN
@		IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar	CAHN
@			0.02MG/ML	A072083	001	Apr 11, 1989	Mar	CAHN
@			0.02MG/ML	A072084	001	Apr 11, 1989	Mar	CAHN
@			0.02MG/ML	A072085	001	Apr 11, 1989	Mar	CAHN
@			0.4MG/ML	A072086	001	Apr 11, 1989	Mar	CAHN
@			0.4MG/ML	A072087	001	Apr 11, 1989	Mar	CAHN
@			0.4MG/ML	A072088	001	Apr 11, 1989	Mar	CAHN
@			0.4MG/ML	A072089	001	Apr 11, 1989	Mar	CAHN
@			0.4MG/ML	A072090	001	Apr 11, 1989	Mar	CAHN
@			1MG/ML	A072091	001	Apr 11, 1989	Mar	CAHN

INJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE

@	1MG/ML	A072092	001	Apr 11, 1989	Mar CAHN
@	1MG/ML	A072093	001	Apr 11, 1989	Mar CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr CAHN
----	--------------------	----------------------------	---------	-----	--------------	----------

NAPROXEN

SUSPENSION; ORAL
NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr CAHN
----	---	----------------	---------	---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL
BYSTOLIC

		FOREST LABS	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Apr CTEC
AB			EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Mar CFTG
			EQ 5MG BASE	N021742	003	Dec 17, 2007	Apr CTEC
AB			EQ 5MG BASE	N021742	003	Dec 17, 2007	Mar CFTG
			EQ 10MG BASE	N021742	004	Dec 17, 2007	Apr CTEC
AB			EQ 10MG BASE	N021742	004	Dec 17, 2007	Mar CFTG
	+		EQ 20MG BASE	N021742	005	Oct 08, 2008	Apr CTEC
AB	+		EQ 20MG BASE	N021742	005	Oct 08, 2008	Mar CFTG

NEBIVOLOL HYDROCHLORIDE

	@	AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr DISC
AB			EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar NEWA
	@		EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr DISC
AB			EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar NEWA
	@		EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr DISC
AB			EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA
	@		EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC
AB			EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
NEFAZODONE HYDROCHLORIDE

	@	IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr CAHN
	@		100MG	A076072	002	Sep 16, 2003	Apr CAHN
	@		150MG	A076072	003	Sep 16, 2003	Apr CAHN
	@		200MG	A076072	004	Sep 16, 2003	Apr CAHN
	@		250MG	A076072	005	Sep 16, 2003	Apr CAHN
AB		SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr CAHN
AB			100MG	A076409	002	Sep 16, 2003	Apr CAHN
AB			150MG	A076409	003	Sep 16, 2003	Apr CAHN
AB			200MG	A076409	004	Sep 16, 2003	Apr CAHN
AB			250MG	A076409	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE; IV (INFUSION)
ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar CAHN
---	----------------------	---------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan NEWA
		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan NEWA

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE

AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar CAHN
AB		20MG	A202644	002	Apr 25, 2013	Mar CAHN

NILUTAMIDE

TABLET;ORAL
NILANDRON

@ CONCORDIA PHARMS INC 50MG N020169 001 Sep 19, 1996 Apr CAHN
+ 150MG N020169 002 Apr 30, 1999 Apr CAHN

NIMODIPINE

CAPSULE;ORAL
NIMODIPINE

AB + BANNER LIFE SCIENCES 30MG A076740 001 Jan 17, 2008 Jan CAHN

NINTEDANIB ESYLATE

CAPSULE;ORAL
OFEV

BOEHRINGER INGELHEIM EQ 100MG BASE N205832 001 Oct 15, 2014 Mar CAIN
+ EQ 150MG BASE N205832 002 Oct 15, 2014 Mar CAIN

NORETHINDRONE

TABLET;ORAL-28
NOR-QD

AB1 + ACTAVIS LABS UT INC 0.35MG N017060 001 Mar CAHN

NYSTATIN

SUSPENSION;ORAL
NYSTATIN

AA G AND W LABS INC 100,000 UNITS/ML A062349 001 Jul 14, 1982 Apr CAHN
@ 100,000 UNITS/ML A062776 001 Dec 17, 1987 Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM;0.1% A062367 001 May 28, 1985 Mar CMFD

OINTMENT;TOPICAL
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM;0.1% A062733 001 Mar 09, 1987 Mar CMFD

OLANZAPINE

TABLET;ORAL
OLANZAPINE

AB IVAX PHARMS INC 20MG A077301 001 Apr 29, 2015 Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB MACLEODS PHARMS LTD 5MG A203044 001 Feb 20, 2015 Feb NEWA
AB 10MG A203044 002 Feb 20, 2015 Feb NEWA
AB 15MG A203044 003 Feb 20, 2015 Feb NEWA
AB 20MG A203044 004 Feb 20, 2015 Feb NEWA
AB ORCHID HLTHCARE 5MG A202937 001 Mar 02, 2015 Feb NEWA
AB 10MG A202937 002 Mar 02, 2015 Feb NEWA
AB 15MG A202937 003 Mar 02, 2015 Feb NEWA
AB 20MG A202937 004 Mar 02, 2015 Feb NEWA

OLAPARIB

CAPSULE;ORAL
LYNPARZA

ASTRAZENECA PHARMS 50MG N206162 001 Dec 19, 2014 Jan CTNA

>A> OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

>A> SPRAY, METERED;INHALATION
>A> STIOLTO RESPIMAT

>A> + BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH;EQ 0.0025MG N206756 001 May 21, 2015 May NEWA
BASE/INH

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
PAZEO

+ ALCON RES LTD EQ 0.7% BASE N206276 001 Jan 30, 2015 Jan NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr	CAHN
AB		8MG	A078602	002	Feb 24, 2011	Apr	CAHN
	ZOFRAN ODT						
AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar	CAHN
AB	+	8MG	N020781	002	Jan 27, 1999	Mar	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

>D>	AP	AGILA SPECLTS	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May	CAHN	
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr	CAHN	
>A>	AP	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May	CAHN	
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr	CAHN	
	AP	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Apr	CAHN	
		@ TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan	DISC	
		ZOFRAN							
	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CAHN
			ZOFRAN PRESERVATIVE FREE						
	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CAHN
			SOLUTION;ORAL						
			ZOFRAN						
	AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar	CAHN
			TABLET;ORAL						
			ZOFRAN						
	AB		NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar	CAHN
	AB			EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar	CAHN
	AB	+		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar	CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION
NORFLEX

		@ IGI LABS INC	30MG/ML	N013055	001		Apr	CAHN
		@ MEDICIS	30MG/ML	N013055	001		Mar	DISC
		ORPHENADRINE CITRATE						
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar	CRLD

OXCARBAZEPINE

SUSPENSION;ORAL
OXCARBAZEPINE

AB	SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr	CAHN
----	--------------------	-----------	---------	-----	--------------	-----	------

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar	CAHN
		GEL, METERED;TRANSDERMAL						
		GELNIQUE 3%						
	+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar	CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL
GELNIQUE

+	ACTAVIS LABS UT INC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Mar	CAHN
---	---------------------	--------------------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

>A>	AA	ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May	NEWA
	AA	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr	NEWA
		TABLET;ORAL						
		OXAYDO						
>D>		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	May	CAHN
			5MG	N202080	001	Jun 17, 2011	Mar	CTNA
>D>			7.5MG	N202080	002	Jun 17, 2011	May	CAHN
			7.5MG	N202080	002	Jun 17, 2011	Mar	CTNA
>A>		EGALET LTD	5MG	N202080	001	Jun 17, 2011	May	CAHN

TABLET; ORAL							
OXAYDO							
>A>		7.5MG		N202080	002	Jun 17, 2011	May CAHN
	OXYCODONE HYDROCHLORIDE						
AB	ACTAVIS ELIZABETH	5MG		A076636	003	Apr 07, 2015	Mar NEWA
AB	VINTAGE PHARMS	10MG		A077712	004	Apr 13, 2015	Mar NEWA
AB		20MG		A077712	005	Apr 13, 2015	Mar NEWA
<u>OXYMORPHONE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE; ORAL							
OXYMORPHONE HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	5MG		A203506	001	Apr 24, 2015	Apr NEWA
AB		7.5MG		A203506	002	Apr 24, 2015	Apr NEWA
AB		10MG		A203506	003	Apr 24, 2015	Apr NEWA
AB		15MG		A203506	004	Apr 24, 2015	Apr NEWA
AB		20MG		A203506	005	Apr 24, 2015	Apr NEWA
AB		30MG		A203506	006	Apr 24, 2015	Apr NEWA
AB		40MG		A203506	007	Apr 24, 2015	Apr NEWA
<u>OXYTOCIN</u>							
INJECTABLE; INJECTION							
OXYTOCIN							
AP	+ EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)		N018243	001		Feb CAHN
AP	+	100USP UNITS/10ML (10USP UNITS/ML)		N018243	002	Jan 10, 2007	Feb CAHN
<u>PACLITAXEL</u>							
INJECTABLE; INJECTION							
PACLITAXEL							
AP	MYLAN PHARMS INC	6MG/ML		A091540	001	Sep 29, 2011	Apr CAHN
<u>PALBOCICLIB</u>							
CAPSULE; ORAL							
IBRANCE							
	PFIZER INC	75MG		N207103	001	Feb 03, 2015	Feb NEWA
		100MG		N207103	002	Feb 03, 2015	Feb NEWA
	+	125MG		N207103	003	Feb 03, 2015	Feb NEWA
<u>PALIPERIDONE PALMITATE</u>							
SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR							
INVEGA TRINZA							
>A>	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)		N207946	001	May 18, 2015	May NEWA
>A>		410MG/1.315ML (311.79MG/ML)		N207946	002	May 18, 2015	May NEWA
>A>		546MG/1.75ML (312MG/ML)		N207946	003	May 18, 2015	May NEWA
>A>	+	819MG/2.625ML (312MG/ML)		N207946	004	May 18, 2015	May NEWA
<u>PAMIDRONATE DISODIUM</u>							
INJECTABLE; INJECTION							
PAMIDRONATE DISODIUM							
AP	MYLAN PHARMS INC	30MG/10ML (3MG/ML)		A078520	001	Oct 31, 2008	Apr CAHN
AP		90MG/10ML (9MG/ML)		A078520	002	Oct 31, 2008	Apr CAHN
<u>PANCURONIUM BROMIDE</u>							
INJECTABLE; INJECTION							
PANCURONIUM BROMIDE							
	@ IGI LABS INC	1MG/ML		A072210	001	Mar 31, 1988	Mar CAHN
	@	2MG/ML		A072211	001	Mar 31, 1988	Mar CAHN
	@	2MG/ML		A072212	001	Mar 31, 1988	Mar CAHN
	@	2MG/ML		A072213	001	Mar 31, 1988	Mar CAHN
<u>PANOBINOSTAT</u>							
CAPSULE; ORAL							
FARYDAK							
	NOVARTIS PHARMS CORP	10MG		N205353	001	Feb 23, 2015	Feb NEWA
		15MG		N205353	002	Feb 23, 2015	Feb NEWA
	+	20MG		N205353	003	Feb 23, 2015	Feb NEWA
<u>PANOBINOSTAT LACTATE</u>							
CAPSULE; ORAL							
FARYDAK							
	NOVARTIS PHARMS CORP	EQ 10MG BASE		N205353	001	Feb 23, 2015	Mar CAIN
		EQ 10MG BASE		N205353	001	Feb 23, 2015	Mar CPOT
		EQ 15MG BASE		N205353	002	Feb 23, 2015	Mar CAIN

CAPSULE;ORAL
FARYDAK

		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CPOT
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CAIN
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CPOT

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar	CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar	CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr	CAHN

PARICALCITOL

CAPSULE;ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar	CAHN
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
BONTRIL

@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan	DISC
+	SANDOZ	105MG	N018074	001		Jan	CTEC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan	NEWA
		10%	N207926	002	Jan 15, 2015	Jan	NEWA

PHENYTOIN SODIUM

CAPSULE;ORAL
PHENYTOIN SODIUM

>A>	AB	AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May	NEWA
-----	----	----------------------	----------------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION
PHENYTOIN SODIUM

AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001		Feb	CAHN
----	---	--------------------	---------	---------	-----	--	-----	------

PHYTONADIONE

INJECTABLE;INJECTION
AQUAMEPHYTON

@	IGI LABS INC	1MG/0.5ML	N012223	002		Apr	CAHN
@		10MG/ML	N012223	001		Apr	CAHN

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL
PILOCARPINE HYDROCHLORIDE

AB		ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar	CAHN
----	--	----------------------	-----	---------	-----	--------------	-----	------

PINDOLOL

TABLET;ORAL
PINDOLOL

@	G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr	CAHN
@		5MG	A073687	001	Feb 26, 1993	Apr	CAHN
@		5MG	A074123	001	Apr 17, 1997	Apr	CAHN
@		10MG	A073661	002	Oct 31, 1993	Apr	CAHN
@		10MG	A073687	002	Feb 26, 1993	Apr	CAHN

	TABLET;ORAL								
	PINDOLOL								
	@	10MG			A 074123	002	Apr 17, 1997	Apr	CAHN
	<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>								
	INJECTABLE;INJECTION								
	PIPERACILLIN AND TAZOBACTAM								
AP	AGILA SPECLTS	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL			A 065458	002	Aug 15, 2014	Mar	CPOT
	<u>PIRBUTEROL ACETATE</u>								
	AEROSOL, METERED;INHALATION								
	MAXAIR								
	@ MEDICIS	EQ 0.2MG BASE/INH			N 020014	001	Nov 30, 1992	Jan	DISC
	<u>PIRFENIDONE</u>								
	CAPSULE;ORAL								
	ESBRIET								
	+ GENENTECH INC	267MG			N 022535	001	Oct 15, 2014	Feb	CAHN
	<u>PIROXICAM</u>								
	CAPSULE;ORAL								
	PIROXICAM								
>A>	AB	MYLAN PHARMS INC	10MG		A 074116	001	Jun 15, 1993	May	CAHN
>A>	AB		20MG		A 074118	001	Jun 15, 1993	May	CAHN
>D>	AB	NOSTRUM LABS	10MG		A 074116	001	Jun 15, 1993	May	CAHN
>D>	AB		20MG		A 074118	001	Jun 15, 1993	May	CAHN
	<u>PODOFILOX</u>								
	GEL;TOPICAL								
	CONDYLOX								
	+ ACTAVIS LABS UT INC	0.5%			N 020529	001	Mar 13, 1997	Feb	CAHN
	SOLUTION;TOPICAL								
	CONDYLOX								
AT	+ ACTAVIS LABS UT INC	0.5%			N 019795	001	Dec 13, 1990	Jan	CAHN
	PODOFILOX								
>A>	AT	BAUSCH AND LOMB INC	0.5%		A 090184	001	Jul 21, 2010	May	CAHN
>D>	AT	PRECISION DERMAT	0.5%		A 090184	001	Jul 21, 2010	May	CAHN
	<u>POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE</u>								
	FOR SOLUTION;ORAL								
	PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE								
AA	STRIDES ARCOLAB LTD	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT			A 204559	001	Apr 13, 2015	Mar	NEWA
	<u>POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE								
AT	ALCON RES LTD	10,000 UNITS/ML;EQ 1MG BASE/ML			A 064211	001	Apr 13, 1998	Jan	CAHN
	<u>PONATINIB HYDROCHLORIDE</u>								
	TABLET;ORAL								
	ICLUSIG								
	ARIAD	EQ 30MG BASE			N 203469	003	Apr 23, 2015	Apr	NEWA
	<u>POTASSIUM CHLORIDE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	POTASSIUM CHLORIDE								
AB2	MYLAN PHARMS INC	8MEQ			A 204662	001	Aug 21, 2014	Feb	CPOT
AB2		10MEQ			A 204662	002	Aug 21, 2014	Feb	CPOT
	<u>PREDNICARBATE</u>								
	OINTMENT;TOPICAL								
	DERMATOP								
AB	+ VALEANT PHARMS NORTH	0.1%			N 019568	001	Sep 23, 1991	Apr	CAHN

PREGABALIN

CAPSULE;ORAL
LYRICA

	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Apr	CTEC
		50MG	N021446	002	Dec 30, 2004	Apr	CTEC
		75MG	N021446	003	Dec 30, 2004	Apr	CTEC
		100MG	N021446	004	Dec 30, 2004	Apr	CTEC
		150MG	N021446	005	Dec 30, 2004	Apr	CTEC
		200MG	N021446	006	Dec 30, 2004	Apr	CTEC
		225MG	N021446	007	Dec 30, 2004	Apr	CTEC
+		300MG	N021446	008	Dec 30, 2004	Apr	CTEC

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb	CAHN
----	---	--------------------	----------------	---------	-----	--------------	-----	------

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
AB			200MG	A200900	002	Aug 16, 2013	Jan	CAHN

GEL;VAGINAL
CRINONE

		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb	CAHN
+			8%	N020701	002	Jul 31, 1997	Feb	CAHN

INJECTABLE;INJECTION
PROGESTERONE

AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar	CAHN
----	---	---------------------	---------	---------	-----	--	-----	------

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL
PHENERGAN

	@	DELCOR ASSET CORP	12.5MG	N010926	002		Apr	CAHN
	@		25MG	N010926	001		Apr	CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN
AB			25MG	A040673	002	Mar 05, 2008	Mar	CAHN
AB			50MG	A040673	003	Mar 05, 2008	Mar	CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

>D>	AB	+	ASTRAZENECA	EQ 25MG BASE	N020639	001	Sep 26, 1997	May	CAHN
>D>	AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May	CAHN
>D>	AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May	CAHN
>D>		@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May	CAHN
>D>	AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May	CAHN
>D>	AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May	CAHN
>D>	AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May	CAHN
>A>	AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May	CAHN
>A>	AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May	CAHN
>A>	AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May	CAHN
>A>		@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May	CAHN
>A>	AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May	CAHN
>A>	AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May	CAHN
>A>	AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr	CAHN
AB			EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr	CAHN
AB			EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr	CAHN
AB			EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr	CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE SULFATE

+ G AND W LABS INC 300MG

A040045 001 Jun 30, 1994 Apr CAHN

QUININE SULFATE

CAPSULE;ORAL
QUININE SULFATE

AB LUPIN LTD 324MG

A203112 001 Apr 24, 2015 Apr NEWA

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL
RALOXIFENE HYDROCHLORIDE

AB WATSON LABS INC 60MG

A200825 001 Jan 21, 2015 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 150MG BASE
@ EQ 300MG BASE

A075439 001 Apr 19, 2000 Apr CAHN

A075439 002 Apr 19, 2000 Apr CAHN

REPAGLINIDE

TABLET;ORAL
REPAGLINIDE

AB STANDARD CHEM PHARM 0.5MG

A091517 001 Apr 24, 2015 Apr NEWA

AB 1MG

A091517 002 Apr 24, 2015 Apr NEWA

AB 2MG

A091517 003 Apr 24, 2015 Apr NEWA

RIFAMPIN

INJECTABLE;INJECTION
RIFAMPIN

AP MYLAN PHARMS INC 600MG/VIAL

A065421 001 May 22, 2008 Apr CAHN

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL
ATELVIA

>D> + WARNER CHILCOTT LLC 35MG

N022560 001 Oct 08, 2010 May CFTG

>A> AB + 35MG

N022560 001 Oct 08, 2010 May CFTG

>A> RISEDRONATE SODIUM

>A> AB TEVA PHARMS USA 35MG

A203217 001 May 18, 2015 May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB SUN PHARM INDS LTD 0.5MG

A077542 001 Aug 06, 2010 Apr CAHN

AB 1MG

A077542 002 Aug 06, 2010 Apr CAHN

AB 2MG

A077542 003 Aug 06, 2010 Apr CAHN

AB 3MG

A078474 001 Aug 06, 2010 Apr CAHN

AB 4MG

A078474 002 Aug 06, 2010 Apr CAHN

RIVAROXABAN

TABLET;ORAL
XARELTO

JANSSEN PHARMS 10MG

N022406 001 Jul 01, 2011 Apr CRLD

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
RIVASTIGMINE TARTRATE

>A> AB ORCHID HLTHCARE EQ 1.5MG BASE

A090879 001 Jun 10, 2015 May NEWA

>A> AB EQ 3MG BASE

A090879 002 Jun 10, 2015 May NEWA

>A> AB EQ 4.5MG BASE

A090879 003 Jun 10, 2015 May NEWA

>A> AB EQ 6MG BASE

A090879 004 Jun 10, 2015 May NEWA

ROFLUMILAST

TABLET;ORAL
DALIRESP

+ ASTRAZENECA PHARMS 500MCG

N022522 001 Feb 28, 2011 Mar CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr	CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr	CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr	CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr	CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr	CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr	CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr	CAHN

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar	CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan	NEWA
AB	+ NOVARTIS	1MG/72HR	N017874	001		Jan	CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ G AND W LABS INC 5MG
 @ 5MG
 @ 5MG

A074537	001	Aug 02, 1996	Apr	CAHN
A074744	001	Jan 27, 1997	Apr	CAHN
A074756	001	Nov 25, 1998	Apr	CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May	DISC
>A>		@	EQ 25MG BASE	A077864	001	Aug 10, 2009	May	DISC
>D>	AB		EQ 50MG BASE	A077864	002	Aug 10, 2009	May	DISC
>A>		@	EQ 50MG BASE	A077864	002	Aug 10, 2009	May	DISC
>D>	AB		EQ 100MG BASE	A077864	003	Aug 10, 2009	May	DISC
>A>		@	EQ 100MG BASE	A077864	003	Aug 10, 2009	May	DISC
	AB	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr	CAHN
	AB		EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr	CAHN
	AB		EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr	CAHN
			EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr	CAHN
			EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr	CAHN

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS

REVATIO

AP	+ PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar	CFTG
AP	AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar	NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

	+ ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar	CAHN
		8MG	N022206	002	Oct 08, 2008	Mar	CAHN

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr	CAHN
AB		10MG	A076285	002	Dec 20, 2006	Apr	CAHN
AB		20MG	A076285	003	Dec 20, 2006	Apr	CAHN
AB		40MG	A076285	004	Dec 20, 2006	Apr	CAHN
AB		80MG	A076285	005	Jun 23, 2006	Apr	CAHN

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

AP	EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb	CAHN
	SODIUM CHLORIDE 0.9%						
	EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb	CAHN

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN
		112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN
+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT
		1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr CAHN
		@	400uCi	N018671	003	May 27, 1982	Apr CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE

KVK TECH

15GM/BOT

A040905 002 Apr 03, 2015 Mar NEWA

KAYEXALATE

AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr CAHN
----	---	----------------------	-------------	---------	-----	--	----------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN FLEXPRO

NOVO NORDISK INC

30MG/3ML

N021148 011 Jan 23, 2015 Jan NEWA

NORDITROPIN NORDIFLEX

NOVO NORDISK INC

30MG/3ML

N021148 007 Mar 10, 2009 Mar CMFD

@

30MG/3ML

N021148 007 Mar 10, 2009 Jan DISC

NUTROPIN

BX	+	GENENTECH	10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC
----	---	-----------	-----------	---------	-----	--------------	----------

ZOMACTON

BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
----	---	---------	----------	---------	-----	--------------	----------

BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr CRLD
----	--	--	-----------	---------	-----	--------------	----------

BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar NEWA
----	---	--	-----------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+ ALTATHERA PHARMS LLC

150MG/10ML (15MG/ML)

N022306 001 Jul 02, 2009 Apr CAHN

TABLET; ORAL

BETAPACE

AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar CAHN
-----	--	-------------------	------	---------	-----	--------------	----------

AB1			120MG	N019865	005	Apr 20, 1994	Mar CAHN
-----	--	--	-------	---------	-----	--------------	----------

AB1	+		160MG	N019865	002	Oct 30, 1992	Mar CAHN
-----	---	--	-------	---------	-----	--------------	----------

AB1			240MG	N019865	003	Oct 30, 1992	Mar CAHN
-----	--	--	-------	---------	-----	--------------	----------

		@	320MG	N019865	004	Oct 30, 1992	Mar CAHN
--	--	---	-------	---------	-----	--------------	----------

SUCRALFATE

TABLET; ORAL

SUCRALFATE

>A>	AB	MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May CAHN
-----	----	------------------	-----	---------	-----	--------------	----------

>D>	AB	NOSTRUM LABS	1GM	A074415	001	Jun 08, 1998	May CAHN
-----	----	--------------	-----	---------	-----	--------------	----------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARON

AB	+	VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar CAHN
----	---	----------------------	-----	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM

AT		AKORN	10%	A040215	001	May 25, 1999	Mar CMFD
----	--	-------	-----	---------	-----	--------------	----------

SULFANILAMIDE

CREAM;VAGINAL
SULFANILAMIDE

@ G AND W LABS INC 15% A088718 001 Sep 19, 1985 Apr CAHN

SUMATRIPTAN SUCCINATE

TABLET;ORAL
SUMATRIPTAN SUCCINATE

AB SUN PHARM INDS LTD EQ 25MG BASE A076554 001 Aug 10, 2009 Apr CAHN
AB EQ 50MG BASE A076554 002 Aug 10, 2009 Apr CAHN
AB EQ 100MG BASE A076572 001 Feb 09, 2009 Apr CAHN

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL
NUCYNTA

>A> + DEPOMED INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012 May CAHN
>D> + JANSSEN PHARMS EQ 20MG BASE/ML N203794 001 Oct 15, 2012 May CAHN

TABLET;ORAL
NUCYNTA

>A> DEPOMED INC EQ 50MG BASE N022304 001 Nov 20, 2008 May CAHN
>A> EQ 75MG BASE N022304 002 Nov 20, 2008 May CAHN
>A> + EQ 100MG BASE N022304 003 Nov 20, 2008 May CAHN
>D> JANSSEN PHARMS EQ 50MG BASE N022304 001 Nov 20, 2008 May CAHN
>D> EQ 75MG BASE N022304 002 Nov 20, 2008 May CAHN
>D> + EQ 100MG BASE N022304 003 Nov 20, 2008 May CAHN

TABLET, EXTENDED RELEASE;ORAL
NUCYNTA ER

>A> DEPOMED INC EQ 50MG BASE N200533 001 Aug 25, 2011 May CAHN
>A> EQ 100MG BASE N200533 002 Aug 25, 2011 May CAHN
>A> EQ 150MG BASE N200533 003 Aug 25, 2011 May CAHN
>A> EQ 200MG BASE N200533 004 Aug 25, 2011 May CAHN
>A> + EQ 250MG BASE N200533 005 Aug 25, 2011 May CAHN
>D> JANSSEN PHARMS EQ 50MG BASE N200533 001 Aug 25, 2011 May CAHN
>D> EQ 100MG BASE N200533 002 Aug 25, 2011 May CAHN
>D> EQ 150MG BASE N200533 003 Aug 25, 2011 May CAHN
>D> EQ 200MG BASE N200533 004 Aug 25, 2011 May CAHN
>D> + EQ 250MG BASE N200533 005 Aug 25, 2011 May CAHN

TELAPREVIR

TABLET;ORAL
INCIVEK

@ VERTEX PHARMS 375MG N201917 001 May 23, 2011 Jan DISC

TEMAZEPAM

CAPSULE;ORAL
TEMAZEPAM

>A> AB VINTAGE PHARMS 7.5MG A201781 001 Jun 04, 2015 May NEWA
>A> AB 15MG A201781 002 Jun 04, 2015 May NEWA
>A> AB 22.5MG A201781 003 Jun 04, 2015 May NEWA
>A> AB 30MG A201781 004 Jun 04, 2015 May NEWA

TEMOZOLOMIDE

CAPSULE;ORAL
TEMOZOLOMIDE

AB AMNEAL PHARMS 5MG A203691 001 May 08, 2015 Apr NEWA
AB 20MG A203691 002 May 08, 2015 Apr NEWA
AB 100MG A203691 003 May 08, 2015 Apr NEWA
AB 140MG A203691 004 May 08, 2015 Apr NEWA
AB 180MG A203691 005 May 08, 2015 Apr NEWA
AB 250MG A203691 006 May 08, 2015 Apr NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB TEVA PHARMS USA 300MG A091612 001 Mar 18, 2015 Mar NEWA
AB + GILEAD SCIENCES INC 300MG N021356 001 Oct 26, 2001 Mar CFTG

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

@	WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb	DISC
---	-----------	---------------	---------	-----	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC	
AB1	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC	
	TESTIM							
AB2	+	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC
	TESTOSTERONE							
	@	ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
	@		1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
>A>	BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN
>A>	BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN
	AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC
	AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC
>D>	BX	TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN
>D>	BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN
	VOGELXO							
AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan	CTEC	

TETRABENAZINE

TABLET; ORAL

XENAZINE

	VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Feb	CAHN
+		25MG	N021894	002	Aug 15, 2008	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr	CRLD
		TETRACYCLINE HYDROCHLORIDE						
	@	IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr	DISC
	@		500MG	A060704	002		Apr	DISC

THEOPHYLLINE

TABLET; ORAL

THEOLAIR

@	MEDICIS	125MG	A086399	001		Mar	DISC
@		250MG	A086399	002		Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

>A>	AB	MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May	CAHN
>A>	AB	+	600MG	A040560	002	Apr 21, 2006	May	CAHN
>D>	AB	NOSTRUM	400MG	A040595	001	Apr 21, 2006	May	CAHN
>D>	AB	+	600MG	A040560	002	Apr 21, 2006	May	CAHN

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

>D>		EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May	CRLD
>A>		+	15MG/VIAL	A075547	001	Apr 02, 2001	May	CRLD

TIGECYCLINE

INJECTABLE; IV (INFUSION)

TIGECYCLINE

>A>	AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May	NEWA
		TYGACIL						
>D>	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May	CFTG
>A>	AP	+	50MG/VIAL	N021821	001	Jun 15, 2005	May	CFTG

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

ISTALOL

AT2	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr	CFTG
		TIMOLOL MALEATE						
AT1		AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr	CTEC
AT1			EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr	CTEC

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT1	ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr	CTEC
AT2	APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr	NEWA
AT1	BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr	CTEC
AT1	FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr	CTEC
AT1	HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr	CTEC
AT1	PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr	CTEC
AT1	WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr	CTEC

TIMOPTIC

AT1	+ ATON	EQ 0.5% BASE	N018086	002		Apr	CTEC
-----	--------	--------------	---------	-----	--	-----	------

TOBRAMYCIN

SOLUTION; INHALATION

KITABIS PAK

AN	PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb	CTEC
----	---------------	-----------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC

TOBREX

AT	+ ALCON LABS INC	0.3%	N050541	001		Mar	CAHN
----	------------------	------	---------	-----	--	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

	@ IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar	CAHN
	@	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar	CAHN
	@	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar	CAHN
	@	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar	CAHN
AP	MYLAN PHARMS INC	EQ 40MG BASE/ML	A065407	001	Mar 11, 2008	Apr	CAHN

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

	@ G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
	@	250MG	N018894	002	Nov 02, 1984	Apr	CAHN
	@	500MG	N018894	003	Nov 02, 1984	Apr	CAHN

TOLCAPONE

TABLET; ORAL

TASMAR

AB	+ VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar	CFTG
----	----------------------	-------	---------	-----	--------------	-----	------

TOLCAPONE

AB	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	NEWA
----	---------------	-------	---------	-----	--------------	-----	------

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

>A>	@ G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May	CAHN
	@	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN
>D>	@ IVAX SUB TEVA PHARMS	EQ 600MG BASE	A074399	001	Mar 28, 1996	May	CAHN

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

AB	IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb	NEWA
AB		2MG	A077006	002	Feb 23, 2015	Feb	NEWA

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

AB	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr	CAHN
AB		100MG	A076327	002	Mar 27, 2009	Apr	CAHN
AB		200MG	A076327	003	Mar 27, 2009	Apr	CAHN
	@ WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr	DISC
	@	50MG	A090353	002	Sep 01, 2010	Apr	DISC
	@	100MG	A090353	003	Sep 01, 2010	Apr	DISC
	@	200MG	A090353	004	Sep 01, 2010	Apr	DISC

TOPIRAMATE

>D>	AB	HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May	DISC
>A>	@	25MG	A091185	001	Nov 25, 2013	May	DISC	
>D>	AB	50MG	A091185	002	Nov 25, 2013	May	DISC	
>A>	@	50MG	A091185	002	Nov 25, 2013	May	DISC	
>D>	AB	100MG	A091185	003	Nov 25, 2013	May	DISC	

TABLET; ORAL		TOPIRAMATE							
>A>	@	100MG		A091185	003	Nov 25, 2013	May	DISC	
>D>	AB	200MG		A091185	004	Nov 25, 2013	May	DISC	
>A>	@	200MG		A091185	004	Nov 25, 2013	May	DISC	

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL		HYCAMTIN							
		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar	CAHN	
	+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar	CAHN	
INJECTABLE; INJECTION		HYCAMTIN							
AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar	CAHN	
		TOPOTECAN HYDROCHLORIDE							
>A>	AP	CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN	
>D>	AP	INNOPHARMA LICENSING	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN	

TORSEMIDE

INJECTABLE; INJECTION		TORSEMIDE							
	@	EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan	DISC	
	@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan	DISC	
	@	LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan	DISC	
	@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan	DISC	

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL		MEKINIST							
		NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar	CAHN	
			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar	CAHN	
	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN	

TRANEXAMIC ACID

INJECTABLE; INJECTION		TRANEXAMIC ACID							
AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD	

TRAZODONE HYDROCHLORIDE

TABLET; ORAL		DESYREL							
>D>	@	APOTHECON	50MG	N018207	001		May	CAHN	
>D>	@		100MG	N018207	002		May	CAHN	
>D>	@		150MG	N018207	003	Mar 25, 1985	May	CAHN	
>D>	@		300MG	N018207	004	Nov 07, 1988	May	CAHN	
>A>	@	PRAGMA PHARMS LLC	50MG	N018207	001		May	CAHN	
>A>	@		100MG	N018207	002		May	CAHN	
>A>	@		150MG	N018207	003	Mar 25, 1985	May	CAHN	
>A>	@		300MG	N018207	004	Nov 07, 1988	May	CAHN	
TABLET, EXTENDED RELEASE; ORAL		OLEPTRO							
	@	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar	DISC	
	@		300MG	N022411	002	Feb 02, 2010	Mar	DISC	

TRETINOIN

CREAM; TOPICAL		RENOVA							
	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN	
AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr	CAHN	
RETIN-A									
AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN	

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL		TRIAMCINOLONE ACETONIDE							
AT		G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD	
AT			0.1%	A089798	001	May 31, 1991	Apr	CMFD	
TRIDERM									
AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA	
AT			0.5%	A088042	003	Mar 25, 2015	Mar	NEWA	

LOTION; TOPICAL
 TRIAMCINOLONE ACETONIDE

AT G AND W LABS INC 0.1% A089129 001 Aug 14, 1986 Mar CMFD

OINTMENT; TOPICAL
 KENALOG

AT DELCOR ASSET CORP 0.025% N011600 003 Mar CMFD
 AT 0.1% N011600 001 Mar CMFD

SPRAY; TOPICAL
 KENALOG

AT + RANBAXY 0.147MG/GM N012104 001 Mar CFTG
 TRIAMCINOLONE ACETONIDE
 AT PERRIGO UK FINCO 0.147MG/GM A205782 001 Apr 13, 2015 Mar NEWA

TRIAMTERENE

CAPSULE; ORAL
 DYRENIUM

CONCORDIA PHARMS INC 50MG N013174 001 Apr CAHN
 + 100MG N013174 002 Apr CAHN

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR
 TRELSTAR

+ ACTAVIS LABS UT INC EQ 3.75MG BASE/VIAL N020715 001 Jun 15, 2000 Jan CAHN
 + EQ 11.25MG BASE/VIAL N021288 001 Jun 29, 2001 Jan CAHN
 + EQ 22.5MG BASE/VIAL N022437 001 Mar 10, 2010 Jan CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

>D> SANCTURA XR
 >D> AB + ALLERGAN 60MG N022103 001 Aug 03, 2007 May DISC
 >A> @ 60MG N022103 001 Aug 03, 2007 May DISC
 TROSPIUM CHLORIDE
 >D> AB ACTAVIS LABS FL INC 60MG A091289 001 Oct 12, 2012 May CRLD
 >A> AB + 60MG A091289 001 Oct 12, 2012 May CRLD
 AB SANDOZ INC 60MG A091635 001 Apr 29, 2015 Apr NEWA

TABLET; ORAL

>D> SANCTURA
 >D> AB + ALLERGAN 20MG N021595 001 May 28, 2004 May DISC
 >A> @ 20MG N021595 001 May 28, 2004 May DISC
 TROSPIUM CHLORIDE
 >D> AB GLENMARK GENERICS 20MG A091575 001 Aug 13, 2010 May CRLD
 >A> AB + 20MG A091575 001 Aug 13, 2010 May CRLD

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
 RESCULA

>A> + R-TECH UENO LTD 0.15% N021214 001 Aug 03, 2000 May CAHN
 >D> + SUCAMPO PHARMA LLC 0.15% N021214 001 Aug 03, 2000 May CAHN
 + 0.15% N021214 001 Aug 03, 2000 Jan CAHN

URSODIOL

CAPSULE; ORAL
 ACTIGALL

@ ACTAVIS LABS UT INC 150MG N019594 001 Dec 31, 1987 Mar CAHN
 AB + 300MG N019594 002 Dec 31, 1987 Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
 VALACYCLOVIR HYDROCHLORIDE

AB HETERO LABS LTD V EQ 1GM BASE A203047 002 Apr 08, 2015 Mar NEWA
 AB EQ 500MG BASE A203047 001 Apr 08, 2015 Mar NEWA
 AB SUN PHARM INDS LTD EQ 1GM BASE A076588 002 Jan 31, 2007 Apr CAHN
 AB EQ 500MG BASE A076588 001 Jan 31, 2007 Apr CAHN

VALPROIC ACID

CAPSULE; ORAL
 VALPROIC ACID

AB BANNER LIFE SCIENCES 250MG A073484 001 Jun 29, 1993 Jan CAHN

CAPSULE, DELAYED RELEASE; ORAL
 STAVZOR

@ BANNER LIFE SCIENCES 125MG N022152 001 Jul 29, 2008 Jan CAHN

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR

@	250MG	N022152	002	Jul 29, 2008	Jan CAHN
@	500MG	N022152	003	Jul 29, 2008	Jan CAHN

VALSARTAN

TABLET;ORAL
VALSARTAN

>A>	AB	PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May NEWA
>A>	AB		80MG	A204821	002	Jun 09, 2015	May NEWA
>A>	AB		160MG	A204821	003	Jun 09, 2015	May NEWA
>A>	AB		320MG	A204821	004	Jun 09, 2015	May NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL
VANCOMYCIN HYDROCHLORIDE

AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA

INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

>D>	AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	May CAHN
	AP	MYLAN PHARMS INC	EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Apr CAHN
>A>	AP		EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	May CAHN
	AP		EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Apr CAHN

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL
STAXYN

AB	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG
AB		WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VECURONIUM BROMIDE

INJECTABLE;INJECTION
VECURONIUM BROMIDE

AP	MYLAN PHARMS INC	10MG/VIAL	A090243	001	May 11, 2010	Apr CAHN
AP		20MG/VIAL	A090243	002	May 11, 2010	Apr CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

>A>	AB	YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
>A>	AB		EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
>A>	AB		EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
>A>	AB		EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
>A>	AB		EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
VERELAN

AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB		240MG	N019614	002	May 29, 1990	Apr CAHN
	+	360MG	N019614	004	May 10, 1996	Apr CAHN

VERELAN PM

AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB		200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE;INJECTION

ISOPTIN

@	MT ADAMS	2.5MG/ML	N018485	001		Apr CAHN
---	----------	----------	---------	-----	--	----------

TABLET;ORAL

ISOPTIN

@	MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CAHN
@		80MG	N018593	001	Mar 08, 1982	Apr CAHN
@		120MG	N018593	002	Mar 08, 1982	Apr CAHN

VERTEPORFIN

INJECTABLE; INJECTION
VISUDYNE

	+	VALEANT LUXEMBOURG	15MG/VIAL		N021119	001	Apr 12, 2000	Mar	CAHN
--	---	--------------------	-----------	--	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL
VIIBRYD

	+	FOREST LABS LLC	10MG		N022567	001	Jan 21, 2011	Mar	CAHN
			20MG		N022567	002	Jan 21, 2011	Mar	CAHN
			40MG		N022567	003	Jan 21, 2011	Mar	CAHN

ZAFIRLUKAST

TABLET; ORAL
ACCOLATE

AB		PAR PHARM INC	10MG		N020547	003	Sep 17, 1999	Feb	CAHN
AB	+		20MG		N020547	001	Sep 26, 1996	Feb	CAHN

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)
ZOLEDRONIC ACID

AP		FRESENIUS KABI USA	EQ 4MG BASE/5ML		A091516	001	Apr 23, 2015	Apr	NEWA
AP		HOSPIRA INC	EQ 4MG BASE/5ML		A090621	001	Mar 19, 2015	Mar	NEWA
AP		USV NORTH AMERICA	EQ 4MG BASE/5ML		A202923	001	Sep 04, 2014	Mar	CPOT

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

		@ HIKMA	5MG		A078129	001	Apr 30, 2008	Mar	DISC
		@	10MG		A078129	002	Apr 30, 2008	Mar	DISC
AB		SUN PHARM INDS LTD	5MG		A078055	001	Apr 23, 2007	Apr	CAHN
AB			10MG		A078055	002	Apr 23, 2007	Apr	CAHN

TABLET; SUBLINGUAL
INTERMEZZO

>D>		PURDUE PHARMA	1.75MG		N022328	001	Nov 23, 2011	May	CFTG
>A>	AB		1.75MG		N022328	001	Nov 23, 2011	May	CFTG
>D>		+	3.5MG		N022328	002	Nov 23, 2011	May	CFTG
>A>	AB	+	3.5MG		N022328	002	Nov 23, 2011	May	CFTG
>A>		ZOLPIDEM TARTRATE							
>A>	AB	NOVEL LABS INC	1.75MG		A204299	001	Jun 03, 2015	May	NEWA
>A>	AB		3.5MG		A204299	002	Jun 03, 2015	May	NEWA

ZONISAMIDE

CAPSULE; ORAL
ZONISAMIDE

AB		BANNER LIFE SCIENCES	25MG		A077813	001	Aug 16, 2006	Jan	CAHN
AB			50MG		A077813	002	Aug 16, 2006	Jan	CAHN
AB			100MG		A077813	003	Aug 16, 2006	Jan	CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

SUN PHARM INDS LTD	650MG	A 078569	001	Dec 14, 2011	Apr	CAHN
@	650MG	A 090205	001	Nov 18, 2009	Apr	CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL
SHADE UVAGUARD

+ BAYER HEALTHCARE LLC	3%;7.5%;3%	N 020045	001	Dec 07, 1992	Mar	CAHN
------------------------	------------	----------	-----	--------------	-----	------

BUDESONIDE

SPRAY, METERED;NASAL
RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS	0.032MG/SPRAY	N 020746	003	Mar 23, 2015	Mar	NEWA
----------------------	---------------	----------	-----	--------------	-----	------

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC	1%	N 021307	001	Dec 07, 2001	Mar	CAHN
------------------------	----	----------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES	5MG	N 022429	001	Jul 23, 2009	Jan	CAHN
+ BANNER LIFE SCIENCES	10MG	N 022429	004	Jul 23, 2009	Jan	CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES	5MG	N 022429	003	Jul 23, 2009	Jan	CAHN
+ BANNER LIFE SCIENCES	10MG	N 022429	002	Jul 23, 2009	Jan	CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS LTD	5MG	A 077498	001	Dec 27, 2007	Apr	CAHN
SUN PHARM INDS LTD	10MG	A 077498	002	Dec 27, 2007	Apr	CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD	5MG	A 077498	003	Dec 27, 2007	Apr	CAHN
SUN PHARM INDS LTD	10MG	A 077498	004	Dec 27, 2007	Apr	CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS	5MG	A 091116	001	Feb 19, 2015	Feb	NEWA
JUBILANT GENERICS	10MG	A 091116	002	Feb 19, 2015	Feb	NEWA
SANDOZ	5MG	A 078692	001	Feb 14, 2008	Feb	CTNA
+ SANDOZ	10MG	A 078692	002	Feb 14, 2008	Feb	CTNA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

JUBILANT GENERICS	5MG	A 091116	003	Feb 19, 2015	Feb	NEWA
JUBILANT GENERICS	10MG	A 091116	004	Feb 19, 2015	Feb	NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON

@ BAYER HEALTHCARE LLC	8MG	N 007638	001		Mar	CAHN
+ BAYER HEALTHCARE LLC	12MG	N 007638	002		Mar	CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC	8MG;120MG	N 018397	001		Mar	CAHN
------------------------	-----------	----------	-----	--	-----	------

CLOTRIMAZOLE

CREAM;VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC	1%	N 018052	002	Nov 30, 1990	Mar	CAHN
------------------------	----	----------	-----	--------------	-----	------

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC	2%	N 020574	001	Nov 24, 1998	Mar	CAHN
------------------------	----	----------	-----	--------------	-----	------

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC	1%,100MG	N 020289	002	Apr 26, 1993	Mar	CAHN
------------------------	----------	----------	-----	--------------	-----	------

TABLET;VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC	100MG	N 017717	002	Nov 30, 1990	Mar	CAHN
------------------------	-------	----------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A 090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

SUN PHARM INDS LTD 10MG
20MG

A 090283 001 Nov 17, 2009 Apr CAHN

A 090283 002 Nov 17, 2009 Apr CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL 60MG;120MG

A 090818 001 Jan 29, 2015 Jan NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC 600MG;60MG
1.2GM;120MG

A 091071 001 May 27, 2015 May NEWA

A 091071 002 May 27, 2015 May NEWA

>A>
>A>
>A>IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES EQ 200MG FREE ACID AND POTASSIUM
SALT

A 078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BANNER LIFE SCIENCES 200MG

N 021472 001 Oct 18, 2002 Jan CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB EQ 0.035% BASE

N 021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD 1.5MG
OC PHARMA 1.5MG

A 202246 001 Jun 05, 2015 May NEWA

A 202380 001 May 29, 2015 May NEWA

>A>
>A>LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES 1MG
+ 2MG

N 021855 001 Aug 04, 2005 Jan CAHN

N 021855 002 Aug 04, 2005 Jan CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG;125MG

A 077500 001 Sep 06, 2006 Apr CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N 021952 001 Jun 16, 2008 Mar CAHN

SYRUP;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N 020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML

N 020641 003 Nov 19, 2003 Mar CAHN

TABLET;ORAL

LORATADINE

SUN PHARM INDS LTD 10MG

A 076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG

N 021891 001 Aug 23, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL									
CLARITIN REDITABS									
+	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006	Mar	CAHN		
LORATADINE REDIDOSE									
	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007	Apr	CAHN		
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
CLARITIN-D									
+	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar	CAHN		
CLARITIN-D 24 HOUR									
+	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar	CAHN		
LORATADINE AND PSEUDOEPHEDRINE SULFATE									
	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004	Apr	CAHN		
<u>NAPROXEN SODIUM</u>									
CAPSULE;ORAL									
NAPROXEN SODIUM									
+	BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan	CAHN		
	CATALENT	EQ 200MG BASE	A202807	001	Feb 13, 2015	Feb	NEWA		
TABLET;ORAL									
NAPROXEN SODIUM									
	SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	Apr	CAHN		
<u>NICOTINE POLACRILEX</u>									
GUM, CHEWING;BUCCAL									
NICOTINE POLACRILEX									
@	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar	DISC		
@		EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar	DISC		
<u>OMEPRAZOLE; SODIUM BICARBONATE</u>									
CAPSULE;ORAL									
ZEGERID OTC									
+	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN		
FOR SUSPENSION;ORAL									
ZEGERID OTC									
+	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar	CAHN		
<u>OXYMETAZOLINE HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
OCUCLEAR									
	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	Mar	CAHN		
<u>POLYETHYLENE GLYCOL 3350</u>									
FOR SOLUTION;ORAL									
MIRALAX									
+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar	CAHN		
POLYETHYLENE GLYCOL 3350									
	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Jan	CAHN		
<u>PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE;ORAL									
PSEUDOEPHEDRINE HYDROCHLORIDE									
	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005	Apr	CAHN		
<u>RANITIDINE HYDROCHLORIDE</u>									
TABLET;ORAL									
RANITIDINE HYDROCHLORIDE									
@	SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000	Apr	CAHN		
@	WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008	Jan	DISC		

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2015

NO MAY 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006					ODE	Dec 12, 2021
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002					ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729	003				ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729	004				ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729	005				ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021866	001	5006528	Oct 20, 2014	DS DP U-543	ODE	Dec 12, 2021
		5006528	Oct 20, 2014	DS DP U-763		
		5006528*PED	Apr 20, 2015			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	001	5006528	Oct 20, 2014	DS DP U-543		
		5006528	Oct 20, 2014	DS DP U-1632		
		5006528*PED	Apr 20, 2015			
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		
		8338427	Mar 15, 2025	DP U-543		
		8338427	Mar 15, 2025	DP U-1633		
		8338428	Aug 06, 2023	DP U-543		
		8338428	Aug 06, 2023	DP U-1633		
		8399469	Jun 29, 2025	DS		
		8759351	Aug 06, 2023	DP U-1530		
		8759351	Aug 06, 2023	DP U-1633		
		8993761	Sep 25, 2022	DS		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	002	5006528	Oct 20, 2014	DS DP U-543		
		5006528	Oct 20, 2014	DS DP U-1632		
		5006528*PED	Apr 20, 2015			
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		
		8338427	Mar 15, 2025	DP U-543		
		8338427	Mar 15, 2025	DP U-1633		
		8338428	Aug 06, 2023	DP U-543		
		8338428	Aug 06, 2023	DP U-1633		
		8399469	Jun 29, 2025	DS		
		8759351	Aug 06, 2023	DP U-1530		
		8759351	Aug 06, 2023	DP U-1633		
		8993761	Sep 25, 2022	DS		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	003	5006528	Oct 20, 2014	DS DP U-543		
		5006528	Oct 20, 2014	DS DP U-1632		
		5006528*PED	Apr 20, 2015			
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		
		8338427	Mar 15, 2025	DP U-543		
		8338427	Mar 15, 2025	DP U-1633		
		8338428	Aug 06, 2023	DP U-543		
		8338428	Aug 06, 2023	DP U-1633		
		8399469	Jun 29, 2025	DS		
		8759351	Aug 06, 2023	DP U-1530		
		8759351	Aug 06, 2023	DP U-1633		
		8993761	Sep 25, 2022	DS		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001 >A>	8895070	Jun 03, 2029	U-124			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001 >A>	9044484	Oct 30, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CARBDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952	001				NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	001	6417175	Apr 11, 2022	DS DP U-1676		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	002	6417175	Apr 11, 2022	DS DP U-1676		
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829	001	8968753	Mar 14, 2034	U-1672		
		8968753	Mar 14, 2034	U-1673		
<u>CELECOXIB - CELECOXIB</u>						
A 076898	002				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898	004				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	002				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	004				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	002				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	004				PC	Jun 02, 2015
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768	001	8062667	Mar 29, 2029	DP		
		8790700	Mar 15, 2027	DP		
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658	002	8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	003	8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001	8371292	Feb 01, 2028	U-1356		
<u>CICLESONIDE - ZETONNA</u>						
N 202129	001	8371292	Feb 01, 2028	U-1357		
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898	001				PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013	001	8962000	Aug 31, 2025	DP U-1410		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027		U-1690		
	7754230	Dec 10, 2027		U-1690		
	8101593	Mar 02, 2030		DP		
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025		U-1690		
	8367649	Mar 02, 2030		DP		
	8461140	Feb 21, 2028		DP		
	>A> 8546367	Feb 21, 2028		DP U-1690		
	8653058	Mar 02, 2030		DP		
	8846066	Feb 08, 2025		U-1690		
	>A> 8883770	Feb 21, 2028		DP		
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP	U-1412		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS	U-860		
	6673838	Mar 01, 2022	DS	U-1364		
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020		U-1205		
	8088407	Oct 20, 2020		U-1205		
	>A> 9012437	Oct 20, 2020		U-1205		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026		DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	>A> 8784885	Oct 15, 2023		DP U-1552		
	>A> 8784885	Oct 15, 2023		DP U-1553		
	>A> 8784885	Oct 15, 2023		DP U-1554		
	>A> 8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026		DP		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019		U-1472		
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032		DP		
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032		DP		
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032		U-421		
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032		DP		
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030		U-55		
	9017721	Apr 23, 2030		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	>A> 9018192	Jun 13, 2026	U-750			
	>A> 9018192	Jun 13, 2026	U-1170			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001					>A> NCE	May 27, 2020
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002					>A> NCE	May 27, 2020
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017				
	6890898	Feb 02, 2019		U-1651	NC	Jan 30, 2018
	7078381	Feb 02, 2019		U-1652	NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP	U-1651	NCE	Aug 01, 2019
	7459428	Feb 02, 2019		U-1651		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP	U-1653		
	8178541	Aug 12, 2023	DP	U-1654		
	8551957	Oct 19, 2029	DP	U-1651		
	8673927	May 04, 2027	DP	U-1652		
	8846695	Jun 04, 2030		U-1652		
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017				
	6890898	Feb 02, 2019		U-1651	NC	Jan 30, 2018
	7078381	Feb 02, 2019		U-1652	NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP	U-1651	NCE	Aug 01, 2019
	7459428	Feb 02, 2019		U-1651		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP	U-1653		
	8178541	Aug 12, 2023	DP	U-1654		
	8551957	Oct 19, 2029	DP	U-1651		
	8673927	May 04, 2024	DP	U-1652		
	8846695	Jun 04, 2030		U-1652		
	8883805	Nov 26, 2025	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP	U-659	I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP	U-659		
	6900221	Nov 09, 2020	DS DP	U-875		
	6900221	Nov 09, 2020	DS DP	U-1046		
	6900221	Nov 09, 2020	DS DP	U-1403		
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020		U-659		
	7087613	Nov 09, 2020		U-1045		
	7087613	Nov 09, 2020		U-1403		
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	9006224	Jul 01, 2028	U-1681			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	>A> 8511304	Jun 14, 2027	DP U-1424			
	>A> 8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	>A> 8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	002				M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003				M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004				M-154	Mar 18, 2018
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	001	>A> 9023401	Oct 30, 2021	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	002	>A> 9023401	Oct 30, 2021	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	003	>A> 9023401	Oct 30, 2021	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	004	>A> 9023401	Oct 30, 2021	DP		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	8497277	Dec 28, 2026	U-1456	I-702	Jan 29, 2018
		8497277	Dec 28, 2026	U-1491	ODE	Jan 29, 2022
		8497277	Dec 28, 2026	U-1650		
		8957079	Dec 28, 2026	DS DP		
		8999999	Jun 03, 2031	U-1683		
		8999999	Jun 03, 2031	U-1684		
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	002	8871810	Sep 30, 2029	U-1599		
		9012508	Sep 14, 2030	U-981		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	001	8980901	May 12, 2025	U-1678		
<u>IDELALISIB - ZYDELIG</u>						
N 205858	002	8980901	May 12, 2025	U-1678		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	001	8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	002	8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	003	8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	004	8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	005	8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	006	8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	007	8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	001	8992982	Apr 23, 2030	DP		
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	002	8992982	Apr 23, 2030	DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986	005	8920383	Jul 17, 2026	DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536	005	8920383	Jul 17, 2026	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	>A> 6444226	Jun 29, 2020	DP U-1534		>A> NP	Jun 27, 2017
	>A> 6652885	Jun 29, 2020	U-1535			
	>A> 7305986	Jan 16, 2023	DP			
	>A> 7464706	Mar 02, 2023	DP			
	>A> 7648960	Jun 29, 2020	U-1535			
	>A> 7943178	Jun 29, 2020	DP U-1535			
	>A> 7943572	Aug 10, 2026	U-1539			
	>A> 8119593	Aug 11, 2029	U-1537			
	>A> 8146588	Apr 24, 2023	DP			
	>A> 8156936	Jan 16, 2023	DP			
	>A> 8215300	Nov 24, 2022	DP			
	>A> 8258095	Aug 11, 2029	U-1537			
	>A> 8389470	Jun 29, 2020	DP U-1697			
	>A> 8394414	May 15, 2015	DP U-1533			
	>A> 8424518	Oct 17, 2031	DP			
	>A> 8485180	Mar 25, 2030	DP			
	>A> 8499757	Feb 19, 2032	DP			
	>A> 8551528	Jun 11, 2030	DP			
	>A> 8623817	Sep 18, 2029	U-1537			
	>A> 8636001	Jul 12, 2032	DP			
	>A> 8729019	Jun 06, 2028	DP			
	>A> 8734845	Jun 11, 2030	DP			
	>A> 8778403	Jun 11, 2030	DP U-1538			
	>A> 8889099	Jun 29, 2020	DP U-1621			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2016	DS			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	>A> 8474447	Jan 17, 2030	DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		>A> ODE GAIN	Mar 06, 2022 Mar 06, 2025
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		>A> ODE GAIN	Mar 06, 2022 Mar 06, 2025
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP	U-1663		
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					>A> M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					>A> M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	8980327	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	8980327	Dec 01, 2030	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001					I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002					I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003					I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004					I-706 ODE	Feb 17, 2018 Feb 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005					I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS U-1211		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					>A> PC	Jul 04, 2015
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-703	Jan 30, 2018
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	>A> 5712279	Feb 21, 2016	DS U-1317		>A> NCE	Dec 21, 2017
	>A> 6492365	Dec 10, 2019	U-1318		>A> ODE	Dec 21, 2019
	>A> 7932268	Aug 19, 2027	U-1316			
	>A> 8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	>A> 5712279	Feb 21, 2016	DS U-1317		>A> NCE	Dec 21, 2017
	>A> 6492365	Dec 10, 2019	U-1318		>A> ODE	Dec 21, 2019
	>A> 7932268	Aug 19, 2027	U-1316			
	>A> 8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	>A> 5712279	Feb 21, 2016	DS U-1317		>A> NCE	Dec 21, 2017
	>A> 6492365	Dec 10, 2019	U-1318		>A> ODE	Dec 21, 2019
	>A> 7932268	Aug 19, 2027	U-1316			
	>A> 8618135	Mar 07, 2025	U-1316			
<u>LORATADINE - CLARITIN</u>						
N 020641 002	>A> 6132758	Jun 01, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001 >A>	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002 >A>	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003 >A>	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004 >A>	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
>A>	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
>A>	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
>A>	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
>A>	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
>A>	9040083	Feb 15, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	>A> 6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	>A> 7083808	Dec 16, 2019	DP			
	>A> 7247318	Dec 16, 2019	DP			
	>A> 7438930	Dec 16, 2019	DP			
	>A> 8580310	Apr 12, 2022	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028		U-1682		
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032		U-1664		
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028		U-1643		
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP	U-702		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029		U-1640		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	>A> 7056500	Jun 29, 2024	DP U-1185			
	>A> 9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	>A> 7056500	Jun 29, 2024	DP U-1185			
	>A> 9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	>A> 9022022	Feb 28, 2031	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	>A> 8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE - NICODERM CQ</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CQ</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CQ</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001				>A> NC		May 21, 2018
				>A> NCE		Jul 31, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001 >A>	9012501	Feb 07, 2025	DP U-1511			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032 001 >A>	9023391	Aug 16, 2025	DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006					M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007					M-153	Apr 16, 2016
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001 >A>	6077843	May 12, 2017	DP U-543		>A> NP	May 18, 2018
	>A> 6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002 >A>	6077843	May 12, 2017	DP U-543		>A> NP	May 18, 2018
	>A> 6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003 >A>	6077843	May 12, 2017	DP U-543		>A> NP	May 18, 2018
	>A> 6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004 >A>	6077843	May 12, 2017	DP U-543		>A> NP	May 18, 2018
	>A> 6077843*PED	Nov 12, 2017				
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP	U-904		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028		DP		
	9011906	Jun 09, 2028		U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028		DP		
	9011906	Jun 09, 2028		U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028		DP		
	9011906	Jun 09, 2028		U-1262		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028		DP		
	9011906	Jun 09, 2028		U-1262		
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027		U-1601		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	>A> 5653517	Jul 24, 2016		U-1359	I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	>A> 5653517	Jul 24, 2016		U-1359	I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	>A> 5653517	Jul 24, 2016		U-1359	I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	>A> 5653517	Jul 24, 2016		U-1359	I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	>A> 9029533	Dec 22, 2026		U-836		
	>A> 9029533	Dec 22, 2026		U-1283		
	>A> 9029533	Dec 22, 2026		U-1699		
	>A> 9029533	Dec 22, 2026		U-1700		
	>A> 9029533	Dec 22, 2026		U-1701		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	>A> 9029533	Dec 22, 2026		U-836		
	>A> 9029533	Dec 22, 2026		U-1283		
	>A> 9029533	Dec 22, 2026		U-1699		
	>A> 9029533	Dec 22, 2026		U-1700		
	>A> 9029533	Dec 22, 2026		U-1701		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	>A> 9029533	Dec 22, 2026		U-836		
	>A> 9029533	Dec 22, 2026		U-1283		
	>A> 9029533	Dec 22, 2026		U-1699		
	>A> 9029533	Dec 22, 2026		U-1700		
	>A> 9029533	Dec 22, 2026		U-1701		
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	>A> 9023790	Jul 04, 2031	DP	U-1698		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8946252	Jul 24, 2029		U-1481	>A> I-709	May 27, 2018
	8969398	Oct 02, 2029		U-1481		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					>A> PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					>A> PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					>A> PC	Nov 28, 2015
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2016	DS DP U-1115			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	>A> 8841330	Jan 12, 2020	U-1696			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8992989	Nov 16, 2027	DP U-1675			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	>A> 8511304	Jun 14, 2027	DP U-1476			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257	001				D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	001				D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	002				D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	003				D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447	001	>A> 8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447	002	>A> 8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447	003	>A> 8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668		
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447	004	>A> 8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668		

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>